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SUMMARY 
Globally, bladder cancer ranks 11th in terms of incidence and ranks 14th 
in terms of mortality rate amongst all cancers. In Singapore, bladder cancer is 
the 12th most common cancer. However, even though bladder cancer is neither 
as common or deadly, it has the highest lifetime treatment cost per patient. This 
is due to the cancer’s high incidence, recurrence and survival rates.   
 At present, the common therapies for bladder cancer include, 
transurethral resection or cystectomy, intravesical Bacillus Calmette-Guérin 
(BCG) and intravesical chemotherapy. These therapies are used in 
combination, but treatment response remains suboptimal with regards to side 
effects and the prevention of recurrence and progression. Hence, the purpose 
of this thesis is to explore new therapeutics with the objective of improving 
bladder cancer treatment outcomes through the complete extermination of 
bladder cancer cells.  
 In order to achieve this, six compounds, solamargine (SOM), 
solasonine (SON), solasodine (SOD), metformin (MET), propranolol (PRO) and 
captopril (CAP) together with the standard chemotherapy drug, mitomycin c 
(MMC) were evaluated for cytotoxicity against various bladder cancer cell lines. 
Amongst all the compounds, SOM was found to be rapid acting, most potent 
with some selectivity. MET was found to have low potency and was selectively 
potent to bladder cancer cells.  
 To further improve the efficacy of the drugs, drug combination 
treatments were explored with MMC, MET and SOM.  Significantly, synergism 
was observed for SOM and MET drug combination against UMUC-3 cells while 
MMC and SOM drug combination had limited synergism against bladder 
Summary 
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cancer cells. MMC and MET drug combination was observed to be antagonistic 
against bladder cancer cells and hence, healthcare professionals should be 
cautioned against the co-administration of both drugs. 
 Lastly, microarray was performed to identify pathways that were 
affected by SOM treatment. Tumour necrosis factor (TNF) signalling pathway, 
mitogen-activated protein kinase (MAPK) signalling pathway and nuclear 
factor-kappa B (NF-κB) signalling pathway were found to be enriched after 
SOM treatment and it is hypothesised that the sustained activation of Jun N-
terminal kinase (JNK) pathway led to apoptosis and previous studies have 
shown that concurrent activation of NF-κB signalling pathway reduced the pro-
apoptotic effect of JNK activation, suggesting that the treatment of SOM 
together with a NF-κB inhibitor could increase the cytotoxicity of SOM.  
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CHAPTER 1: INTRODUCTION  
1.1. Bladder Cancer: Background 
Worldwide, bladder cancer is the 11th most common cancer [1], with 
430,000 new cases diagnosed in 2012 [2]. At any point in time, 2.7 million 
people have a history of urinary bladder cancer [3]. In terms of cancer deaths, 
bladder cancer ranks 14th globally [1]. Bladder cancer is about four times more 
common in males.  
Risk factors for bladder cancer include smoking and exposure to 
aromatic amines and industrial chemicals [4]. Smoking accounts for an 
estimated 50% of all bladder cancer cases while exposure to aromatic amines 
and industrial chemicals account for 10% [1]. Other causes of bladder cancer 
are radiotherapy and bladder schistosomiasis [1, 5].  
In developed countries, it is predicted that with the decline in smoking 
and banning of carcinogens in work environments, there will be a decrease in 
incidence of bladder cancer. On the other hand, in developing countries, 
increase in smoking and industrialization meant that the burden of bladder 
cancer will increase strongly [3]. Therefore, bladder cancer incidence will 
continue to rise globally [6].  
In Singapore, bladder cancer is the 12th most common cancer, dropping 
from the ninth rank in 2008 to 2012. For the same period, the 5-year age-
standardised relative survival (ASRS) is 70.7% for males and 62.5% for 
females [7]. Throughout the years from 1973 to 2012, there has been a 
decrease in the age-standardised incidence rate (ASIR) as well as age-
standardised mortality rate (ASMR) of the cancer, leading to better ASRS. Even 




it ranks eighth most common cancer amongst Malay males and ninth most 
common cancer amongst Indian males [8].  
Despite its lower incidence rates, bladder cancer has the highest 
lifetime treatment cost per patient amongst all cancers [9]. In the United States, 
the national cost of treating non-muscle invasive bladder cancer (NMIBC) is 
estimated to be $157.5 million over five years [10]. In the United Kingdom, 
NMIBC can cost $82.4 million to manage while muscle invasive bladder cancer 
(MIBC) costs $12,409 per patient [11]. The high costs of managing NMIBC are 
associated with the cancer’s high incidence, recurrence and survival rates as 
patients must commit to lifelong bladder surveillance coupled with prompt 
therapy when recurrence is detected [12].  
 
1.2. Bladder Cancer: Staging and Classification 
Bladder cancer is staged according to the tumour, node, metastasis 
(TNM) classification of malignant tumours [13] (Figure 1 and 2). This system 
was devised by Pierre Denoix and further developed and maintained by the 
Union for International Cancer Control.  
 
 
Figure 1. A graphical illustration of the staging of bladder cancer tumour according 






Figure 2. TNM classification of malignant tumours.  
 
1.2.1. Non-Muscle Invasive Bladder Cancer 
NMIBC refers to tumours that are confined within the mucosa, includes 
tumours of stage Ta, Tis and T1. Tumours of Ta stage are non-invasive 
papillary carcinoma while Tis are carcinoma in situ. T1 tumours invade the sub-
epithelial connective tissue. NMIBC makes up 70% of all bladder cancer 
diagnoses [5, 15].  
NMIBC tumours of Ta and T1 stage are further categorized by World 
Health Organization (WHO) into papillary urothelial neoplasm of low malignant 
potential (PUNLMP), low-grade papillary urothelial carcinoma and high-grade 
papillary urothelial carcinoma [1]. They are categorized according to the 
histological features shown in Table 1 below. This grading allows the tumours 








Papillary neoplasm of low 
malignant potential  
Low-grade papillary carcinoma High-grade papillary carcinoma 
Architecture 
Papillae Delicate Delicate. Occasional fused Fused, branching, and delicate Fused, branching and delicate 
Organization of 
cells 
Identical to normal Polarity identical to normal. 
Any thickness Cohesive 
Predominantly ordered, yet minimal 
crowding and minimal loss of polarity. 
Any thickness. Cohesive 
Predominantly disordered with 
frequent loss of polarity. Any 
thickness. Often discohesive 
Cytology 
Nuclear size Identical to normal May be uniformly enlarged Enlarged with variation in size Enlarged with variation in size 
Nuclear shape Identical to normal Elongated, round-oval, 
uniform 





Fine Fine Mild variation within and between cells Moderate-marked variation both 
within and between cells with 
hyper-chromasia 
Nucleoli Absent Absent to inconspicuous Usually inconspicuous Multiple prominent nucleoli may 
be present 
Mitoses Absent Rare, basal Occasionally at any level Usually frequent, at any level 




Ta tumours of PUNLMP and low grade have negligible risk of 
progression though they have a tendency to recur [5, 17]. Low grade Ta 
tumours can demonstrate a recurrence of 70% [18]. High grade Ta tumours 
have the highest risk of progression at 45%, followed by low grade Ta tumours 
with 11% and PUNLMP tumours at 2% [17]. Hence, grade is an important factor 
determining progression [4] as well as prognostication [17]. NMIBC progression 
and recurrence are also influenced by tumour multiplicity [19, 20] and tumour 
size [17].  
Carcinoma in situ, Tis is a urothelial carcinoma that is flat, non-invasive 
and of high grade. WHO has also further categorized them into [1]: hyperplasia 
(flat lesion without atypia or papillary aspects), reactive atypia (flat lesion with 
atypia), atypia of unknown significance and urothelial dysplasia. T1 tumours 
constitute 5 – 20% of all NMIBC [21, 22]. They are defined as tumours that 
have invaded the lamina propria but not the muscularis propria of the bladder 
[21]. Most T1 tumours are of high grade [17] and such tumours have a 
recurrence rate of 69 – 80% [21]. They also have a 33 – 50% likelihood of 
progression [17, 21, 23].  
Compared to Ta tumours, Tis and T1 tumours demonstrate high 
malignant potential [1]. Together, they account for about 80% of all bladder 
cancers and have an overall rate of recurrence of 60 – 70%  and overall rate of 
progression is 20 – 30% [17]. The five-year survival rate for patients with 
NMIBC is 90% [24].  
 
1.2.2. Muscle Invasive and Metastatic Bladder Cancer 
 Bladder cancer is classified as muscle-invasive when the stage of the 
tumour is stage 2 to 4 [25]. Stage 2 bladder cancer has grown into the muscle 




bladder cancer is no longer confined in the urothelium and invades into 
surrounding organs [5, 26].  
 Compared to NMIBC, the five-year survival rate for patients with MIBC 
decreases if the disease is more advanced at diagnosis. The five-year survival 
rate decreases from 50% to 33% then to 10% for bladder cancer of stage 2, 
stage 3 and stage 4 respectively [24].  
 
1.3. Bladder Cancer: Cell Lines 
There are many human bladder cancer cell lines used in laboratories 
and they are categorised into low grade and high grade cell lines. Amongst 
these, the majority are transitional cell carcinomas (TCC). RT4 is a low grade 
papillary cell line [27] while TCCSUP is a metastatic cell line [28]. Other TCC 
cell lines, T24, UMUC-3, J82, SD and 5637 are muscle invasive cell lines [29, 
30]. An example of a squamous carcinoma cell line is SCaBER [28].  
In this study, three human bladder cancer cell lines were used, namely 
T24, UMUC-3 and J82 which are all muscle-invasive, transitional cell 
carcinomas. One normal uroepithelium cell line, HUC-1 was used as well [31].  
 
1.4. Molecular Mechanisms underlying Bladder Cancer 
 In Ta tumours, fibroblast growth factor receptor (FGFR) 3 alterations 
are common, being found in up to 80% of all Ta tumours [14, 32] (Figure 3). 
FGFR3 mutations are however less common in higher grade tumours. Other 
than FGFR alterations, bladder cancer cells also see the alteration of 
phosphoinositide 3-kinase (PI3K) pathway through upstream receptors and 
downstream activating mutations as well as activation of mitogen-activated 




signal–regulated kinases (ERK) phosphorylation [33]. Hedgehog and 
Wingless-type mouse mammary tumour virus (MMTV) integration site (Wnt) 
signalling pathway was also found to be especially important in MIBC with bone 
morphogenetic proteins pathway activation found to prevent cancer 
progression [34]. Epigenetic modifications are also a feature of bladder cancer, 




Figure 3. Hypothesised pathway of bladder cancer carcinogenesis [14]  
 
1.5. Current Therapies for Non-Muscle Invasive Bladder Cancer 
For patients with NMIBC, two common treatment goals are: reduce 
tumour recurrence and preventing tumour progression. Successful treatment 
of bladder cancer would eliminate the subsequent need for further therapies 
and morbidities associated with the treatment and also avoid the need for more 
aggressive therapy [15].   
Currently, therapies for NMIBC come in the form of: transurethral 
resection of bladder tumours (TURBT), intravesical Bacillus Calmette-Guérin 
(BCG), intravesical chemotherapy, laser-ablation therapy, radiation and 




therapeutic, prophylactic, or adjuvant, administered immediately post-
operation [17].   
1.5.1. Transurethral Resection of Bladder Tumours  
The gold standard treatment of NMIBC is TURBT [17]. During TURBT, 
the bladder tumour is removed together with a margin of normal-looking 
mucosa bordering the tumour. It may also require the removal of the muscularis 
propria at the base of the tumour [37]. This procedure primarily aims to remove 
the papillary non-muscle-invasive tumours completely [38]. Subsequently, the 
tumour tissues can be sent for histological testing to determine the tumour 
stage, grade, histology for prognostication, so as to decide on suitable adjuvant 
therapy [38].  
It is observed that in NMIBC, 50 – 80% of patients have recurrence after 
TURBT [39]. Hence, other than TURBT, it is suggested for patients with T1 or 
high grade tumours, to undergo a second, restaging TURBT four to six weeks 
after the initial resection [17]. Resection that is incomplete, due to an 
underestimation of the extent of tumour invasion, tumour cell seeding or 
aggressive tumour biology can lead to residual tumours in patients [38]. These 
residual tumours are found in up to 75% of patients in the weeks after TURBT 
[38, 40-42]. Restaging TURBT can thus, help to control the disease locally, 
reduce recurrence [43], progression and improve the initial response to BCG 
therapy [44].  
 
1.5.2. Intravesical Bacillus Calmette-Guérin 
BCG as an intravesical immunotherapy has been approved by the US 
Food and Drug Administration (FDA) from 1990 [45]. The success of BCG is 
dependent on the activation of an intact immune system, with the involvement 




lymphocytes and granulocytes [46]. This therapy is able to selectively affect 
bladder cancer cells, sparing normal urothelial cells [46]. Bladder cancer cells 
have demonstrated to be able to internalise BCG in vitro [47], with further work 
showing that they upregulate the expression of major histocompatibility 
complex (MHC) class II and intercellular adhesion molecule-1 (ICAM-1) [48, 49] 
as well as secreting cytokines such as interleukin (IL) -6  following the 
internalisation [50]. It is hypothesised that the activation of NK cells and 
secretion of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) 
eventually leads to the death of bladder cancer cells [46].   
For BCG immunotherapy to succeed, a strong T helper type (Th) 1 
immune response is necessary [51]. A Th1 immune response is associated 
with reduced recurrence and improved survival [52]. This can be seen in the 
elevated levels of Th1 cytokines detected in urine following BCG instillation [53, 
54].  
Intravesical BCG that is used as an adjuvant therapy after TURBT 
should be administered according to the protocol described in Southwest 
Oncology Group (SWOG) trial 8507 [55]. The induction schedule involves six 
weekly intravesical instillations of BCG, followed by the maintenance schedule 
of once weekly for three weeks at three months, six months and every six 
months for a total of three years from the initiation of the therapy [55]. This 
protocol is also known as the 6 + 3 protocol.  
Since its approval, it has been demonstrated that intravesical BCG is 
effective in reducing recurrence [56-58], progression [56, 59] as well as 
improving survival [60, 61] from NMIBC. This is especially so if intravesical 
BCG is used with BCG maintenance [55, 56, 62], increasing the complete 




Compared with other therapies, BCG has shown to be superior in 
efficacy. BCG after TURBT is superior to TURBT alone or TURBT and 
chemotherapy [64, 65] for the prevention of recurrence of NMIBC in patients 
with Ta and T1 tumours [66, 67], at high risk of tumour recurrence [67] and 
intermediate or high-risk status [68]. Besides that, further studies have 
confirmed that the superiority of BCG in the prevention of tumour occurrence 
as compared to epirubicin and interferon [69], mitomycin c (MMC) [70] or 
epirubicin [71]. In terms of complete response rate, BCG provides an additional 
15 – 20% increase in response compared to chemotherapy [64, 72].  
Even though intravesical BCG is higher in efficacy, the use of 
intravesical BCG is also accompanied with more side effects than intravesical 
chemotherapy [56], with its most common local side effect being cystitis [73]. 
This is experienced by 90% of all patients [74, 75]. Various studies report 7 – 
20% of patients discontinuing BCG treatment due to side effects [76-78], with 
less than 5% suffering a major adverse event [79]. Majority of the side effects 
of intravesical BCG develop during the induction and early maintenance 
schedule [77].  
 
1.5.3. Intravesical Chemotherapy 
The aim of intravesical chemotherapy is to kill any circulating tumour 
cell and prevent their implantation following TURBT [4, 80]. It can also eradicate 
any remaining tumour after an incomplete TURBT [80]. Hence, for optimal 
effect, intravesical chemotherapy should be instilled soon after TURBT.  
Intravesical BCG is superior in efficacy but due to the side effects of 
BCG instillation, intravesical chemotherapy is the primary treatment for low risk 
patients [74]. In general, intravesical chemotherapy is not associated with much 




usually accomplished with MMC, doxorubicin, valrubicin or epirubicin [36]. An 
instillation of chemotherapy should be given immediately within 6 – 24 hours of 
TURBT and was shown to significantly reduce recurrence rate compared with 
TURBT alone [82], lowering recurrence by a further 14 – 17% [83]. There are 
however, limited advantages in preventing progression [83]. Comparing the 
various chemotherapeutic agents, none was demonstrated to be better [84]. 
Patients who do not respond to intercalating agents such as doxorubicin can 
then be treated with alkylating agents such as MMC and vice versa [74].  
Most patients are given a one-off instillation of intravesical 
chemotherapy [81]. Studies have shown that a single instillation of intravesical 
chemotherapy performed immediately post-TURBT in low-risk superficial 
bladder cancer remains effective for two years [85-87]. Maintenance schedule 
for intravesical MMC and doxorubicin chemotherapy was not proven to provide 
additional recurrence, progression and survival advantages [88, 89]. 
Furthermore, repeated instillations of chemotherapeutic drugs were reported to 
lead to urothelial atypia, resembling carcinoma in situ [75].  
Since chemotherapy is administered intravesically, the response is 
dependent on both the drug concentration as well as the duration of exposure 
[74]. Other factors that may affect the drug deposition in the bladder are, patient 
hydration status, urine volume and pH, the drug’s physicochemical properties 
and its ability to permeate into the tissues of the bladder [90] and the integrity 
of the urothelium [84].  
The administration of MMC intravesical chemotherapy is difficult and 
has suboptimal efficacy. It is known that the MMC solution is diluted within five 
minutes after instillation due to urine production [91]. Hence, patients are 




before instillation [74, 92]. Since MMC is stable between pH 5 – 8 [93, 94], 
patients are also administered oral sodium bicarbonate prior to treatment to 
alkalinise urine [92]. MMC is administered at 40 mg in 20 mL of sterile water 
[74] and patients would be required to hold their bladder for an hour for the drug 
to take effect [95]. One common side effect of MMC instillation affecting 10% 
of patients is myelosuppression [74].  
 Other than that, the hydrophilic physical property of MMC also limits its 
uptake into the bladder urothelium [96], with passive diffusion being the major 
transport mechanism across the urothelium [97]. Also, MMC has insignificant 
binding to tissues, further lowering its retention in the bladder [98].  
 Since intravesical BCG and intravesical chemotherapy have different 
mechanism of action, the combination of intravesical chemotherapy and BCG 
have been evaluated in several studies. It is proposed that the instillation of 
BCG prior to chemotherapy is able to aid in the absorption and infiltration of 
chemotherapeutic agents into the bladder cell wall. On the other hand, the 
instillation of chemotherapy prior to BCG can lead to chemical cystitis, enabling 
BCG particles to adhere to the bladder cell wall [80]. Sequential treatment using 
intravesical BCG followed by MMC provided additional recurrence, progression 
and survival benefit [99]. However, the use of intravesical MMC followed by 
BCG did not yield additional treatment benefits [100, 101].  
 
1.6. Current Therapies for Muscle Invasive Bladder Cancer 
 For patients with MIBC, treatment goals can include slowing the 
cancer’s spread, reducing tumour size and extending the lifespan of the patient 




MIBC, but alternate therapies that allow for bladder preservation such as 
chemotherapy and radiation are also available [102].   
 
1.6.1. Radical Cystectomy 
 The gold standard treatment for MIBC, which has been in place for 
several decades, is radical cystectomy with pelvic lymphadenectomy [103, 104]. 
Recommended for the majority of patients with MIBC, the aim of radical 
cystectomy is curative [105]. Approximately 21% of all patients diagnosed with 
MIBC elect to undergo radical cystectomy [102]. The five-year survival rate of 
radical cystectomy surpasses that of alternative treatment at 42.2% as 
compared to 20.7% for patients undergoing chemotherapy and/or radiation and 
14.5% for patients choosing surveillance [102]. It is advantageous for patients 
to perform radical surgery as early as possible as delays in treatment can 
increase the probability of extravesical disease by 30% [105]. Despite being 
the gold standard therapy, low adoption rates persist due to poor quality of life 
subsequently, as a result of urinary diversion [102]. Other concerns include 
long recovery time and high risk of erectile dysfunction in men [106].  
 To improve the survival rates post-surgery, neoadjuvant chemotherapy 
is recommended after radical cystectomy [5].  
 
1.6.2. Trimodal Bladder Preservation Therapy 
 Trimodality therapy (TMT) consists of an initial extensive TURBT 
followed by radiation and chemotherapy [107], allowing patients to retain their 
quality of life and avoid side effects of radical cystectomy without compromising 
survival outcomes [108]. This is also an option for patients who are not suitable 
for radical cystectomy [107]. The five-year survival rates of TMT is comparable 




long term survivors, 70 – 75% report normal function of the bladder after TMT 
[110]. Salvage cystectomy, which is performed when patients have incomplete 
response or later develop invasive recurrence disease [109], has a five-year 
survival rate of 25 – 30% [108]. Approximately 30% of patients who underwent 
TMT will eventually require radical cystectomy [107].  
 
1.7. Objective of the Study 
 In view of the treatment shortfalls in bladder cancer, the objective of this 
study is to explore new therapeutics and combination therapies with the aim of 
optimizing bladder cancer treatment – reducing progression and recurrence – 
through the complete extermination of bladder cancer cells.    
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CHAPTER 2: EXPLORATION OF NEW AND OLD DRUGS 
FOR THE TREATMENT OF BLADDER CANCER  
2.1. Summary 
 Intravesical chemotherapy is used as an adjuvant therapy after the 
resectioning of bladder cancer tumour. Even though it has lesser side effects 
as compared to intravesical BCG, it is less efficacious, with higher bladder 
cancer recurrence and lower complete response rate. In this chapter, the cell 
cytotoxicity of MMC, solamargine (SOM), solasonine (SON), solasodine (SOD), 
metformin (MET), propranolol (PRO) and captopril (CAP) were studied through 
cell viability assays against several bladder cancer cell lines and bladder 
epithelium cell line to evaluate for efficacy and selectivity. MMC was found to 
be the most cytotoxic drug but has poor selectivity. SOM performed best out of 
all the glucoalkaloids with the highest efficacy and selectivity. MET while being 
least potent, was able to selectivity inhibit bladder cancer cells. PRO and CAP 
have no cytotoxic effects against bladder cancer cells.  
 
2.2. Introduction 
 Bladder cancer is the 11th most common cancer in the world [1]. Even 
though it has lower incidence rates, high recurrence and survival rates cause 
NMIBC to have the most expensive lifetime treatment cost per patient amongst 
all cancers [9]. In the United States, treatment is expected to cost $157.5 million 
over five years [10]. Intravesical BCG and intravesical chemotherapy after 
TURBT has reduced recurrence, progression and promoting survival [64, 65, 
83]. Intravesical BCG, being the most effective adjuvant therapy [65-72], is 
accompanied with more side effects [56] with 7 – 20% of patients facing 
treatment failure [76-78]. Intravesical chemotherapy on the other hand, has 
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lesser side effects making it the primary treatment for low risk patients [74] 
despite being less effective.  
 Among the chemotherapeutic agents used for intravesical 
chemotherapy, MMC is one of the most used drug as it causes less side effects 
as compared to other agents [90, 112]. MMC is an antibiotic drug that is isolated 
from soil fungus, Streptomyces caespitosus [113]. Through a reduction 
reaction, MMC can be converted to a highly reactive alkylating agent [114]. It 
exerts its effects as an anticancer drug primarily through alkylation and later 
covalently crosslinking of deoxyribonucleic acid (DNA) strands [90]. 
Crosslinking inhibits DNA replication, arresting cells at G2 phase [115], paving 
the way for DNA repair or cell death mechanisms [116]. Other than the 
formation of DNA crosslinks, it is proposed that MMC inhibits thioredoxin 
reductase, thereby resulting in cytotoxicity [117]. Alkylating agents kill both 
cancer cells and normal cells thereby causing side effects and low therapeutic 
index [116]. As MMC has a high molecular weight of 334 Da and low systemic 
absorption of 1 – 5%, toxicities are largely experienced locally [90].    
 The low uptake of MMC into the bladder urothelium is largely due to its 
hydrophilic property [96], since passive diffusion is the major transport 
mechanism across the urothelium [97]. It is also poorly retained in the bladder 
as it has insignificant binding to tissues [98]. In addition, MMC is only stable 
between pH 5 – 8 [93, 94]. These contribute to the sub-optimal efficacy of MMC 
in intravesical chemotherapy. Coupled with the difficulty of administering MMC 
effectively, more efficacious chemotherapeutic agents with lesser side effects 
are explored, with the aim of reducing recurrence, progression and improving 
survival, thereby lowering treatment cost.  
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 In this study, glycoalkaloids, which are SOM, SON and SOD are 
evaluated together with FDA-approved drugs, MET, PRO and CAP with MMC 
as the standard for cell cytotoxicity.  
 
2.2.1. Solamargine, Solasonine, Solasodine  
 Glycoalkaloids are compounds that have both the sugar (solatriose) 
moiety and the alkaloid (solanidine) moiety. SOM and SON are present in 
plants belonging to the family Solanaceae and Liliaceae [118] and can be 
extracted and isolated from plants Solanum nigrum L. [119], Solanum incanum 
L. [120] as well as from the fruits of Solanum sodomaeum L. [121]. In terms of 
structure, both compounds have the same alkaloid moiety, differing only in the 
structure of the sugar moiety [122]. SOD only contains the alkaloid moiety. The 
structures of SOD, SON and SOM are shown below (Figure 4 to 6).  
 
Figure 4. Structure of SOD  
 
 
Figure 5. Structure of SON  




Figure 6. Structure of SOM  
 
 SOD does not demonstrate anticancer activity [123]. On the other hand, 
SOM and SON have been shown to be effective against many cancer cell lines 
[118, 124], such as lung adenocarcinoma [125], non-small-cell lung cancer 
[119], hepatocellular carcinoma [120, 126], cervical carcinoma [127] and breast 
cancer [128]. SOM was found to induce cell death through both intrinsic and 
extrinsic apoptosis pathways [125, 128]. One paper suggested that SOM 
induces apoptosis through the activation of p38 MAPK which subsequently 
leads to the downstream increase in expression of p21 [119]. Other than that, 
SOM was also found to inhibit migration and invasion through the 
downregulation of matrix metalloproteinases (MMP) 2 and 9 proteins [129].  
 SOM and SON have demonstrated specific efficacy against cancer 
cells and that is attributed to the drug’s preferential binding to cancer cells [130]. 
Other than inducing apoptosis, one paper has proposed that both drugs can 
stimulate immune response by increasing the CD4+/CD8+ ratio [127].  
 
2.2.2. Metformin 
 Drug repositioning, or drug repurposing is the identification of new 
indications for existing or failed drugs [131]. Many drugs have multiple targets, 
perturbing a number of cellular pathways and processes, therefore creating 
opportunities for their use in treating other diseases [132]. This, coupled with 
the time-consuming, expensive and frequently unsuccessful process of 
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identification and validation of new molecular entities (NME) [131], makes drug 
repositioning attractive to pharmaceutical companies. Through drug 
repositioning, a 10 to 17 years long drug development process can be reduced 
to 3 to 12 years with increased confidence in the drug’s safety and 
pharmacokinetic profile [133].  
 MET is an antidiabetic drug belonging to a class called biguanide. It is 
widely used as a first line of treatment against type II diabetes [134]. Its 
popularity is attributed to the drug’s low cost and excellent safety profile [135]. 
It can also be safely administered with other antidiabetic agents [135]. As an 
anti-hyperglycemic agent, MET achieves its effect by inhibiting the generation 
of glucose in the liver while stimulating the uptake of glucose in the muscles 
[136, 137]. MET is also able to increase insulin sensitivity [138].  
 Curiously, numerous meta-analyses, cohort studies and 
epidemiological studies have shown that MET is associated with a decrease in 
overall cancer incidence [139-142] and reduced overall cancer mortality in 
diabetes patients [139]. Benefits have also been observed in specific cancers, 
such as lung cancer [143, 144], colorectal cancer [145], hepatocellular 
carcinoma [146], prostate cancer [147] and pancreatic cancer [148].   
 It is proposed that MET exerts its anti-cancer effect through two 
mechanisms, directly and indirectly. In an indirect manner, MET reduces the 
amount of insulin and circulating glucose [149, 150]. Insulin has been shown to 
have mitogenic and pro-survival properties [151, 152], with tumour cells often 
expressing insulin receptors aberrantly [153-155]. High levels of insulin have 
also been proven to lead to the upregulation of the insulin or insulin-like growth 
factor (IGF) signalling pathway, thereby contributing to tumorigenesis [156]. 
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Reduced amounts of circulating glucose can also suppress tumours cells that 
are dependent on aerobic glycolysis, also known as the Warburg effect [157].  
 Lower hepatic energy and lowered adenosine triphosphate (ATP) levels 
leads to liver kinase B1 (LKB1)-mediated activation of adenosine 
monophosphate-activated protein kinase (AMPK) [158, 159], and bringing 
about an inhibition of mechanistic target of rapamycin (mTOR) signalling [160, 
161]. This results in reduced protein synthesis and lower proliferation in vitro in 
tumour cells [162, 163]. 
 The direct target of MET remains under investigation, with the latest 
studies suggesting the mitochondrial respiratory-chain complex 1 [164-166] or 
the mitochondria [167]. Overall, through either mitochondria targets, it is 
observed that cellular respiration is inhibited [168, 169] and citric acid cycle 
activity is reduced [167]. The reduced efficiency of energy metabolism may 
result in toxicity for tumour cells [167]. It also inhibits tumourigenesis by 
inducing cell death under low glucose and low oxygen conditions by reducing 
the activation of hypoxia-inducible factor 1 (HIF-1) under hypoxic conditions 
[169] (Figure 7).  




Figure 7. Impact of MET actions on the mitochondria. Through organic cation 
transporter 1 (OCT1), MET enters the cell and accumulates in the mitochondria. At 
the mitochondria, it inhibits complex I of the electron transport chain and 
mitochondrial glycerol-phosphate dehydrogenase (mGPD), eventually resulting in 
increased AMPK signalling, reduced cyclic adenosine monophosphate 
(cAMP)/Protein kinase A (PKA) signalling, lowered gluconeogenesis and 
increased glycolysis. [166] 
 
2.2.3. Propranolol 
 PRO is a non-selective β-adrenergic receptor blocker, used to manage 
conditions such as high blood pressure, angina, migraine headaches and 
preventing arrhythmias [170]. Aside from these indications, Leaute-Labreze, et 
al. discovered by chance that PRO is effective against infantile haemangioma 
(IH) [171]. IH are vascular benign tumours that affects infants [172]. The 
development of IH follows three stages [173, 174]. Initially, there is a 
proliferation of undifferentiated progenitor cells [175, 176] followed by a 
involuting stage involving the differentiation of progenitor cells into atypical 
vascular endothelial cells [177] and maturation of vasculature [176, 178]. Lastly, 
the involuted stage is where apoptosis happens and the tumour regresses [179, 
180]. The vasculature is replaced eventually replaced by fibroadipose tissue 
[181].  
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 Numerous mechanisms have been proposed to explain how PRO 
induces the regression of IH. PRO was found to cause vasoconstriction [182, 
183], induce apoptosis [184, 185] and inhibit angiogenesis through decreased 
vascular endothelial growth factor (VEGF) signalling [186-189]. Conflicting 
evidences attest that PRO might [190-193] or might not [194-196] reduce 
cancer risk in patients. In vitro, numerous cancers are affected by the β-
adrenergic system [197] and anti-cancer activity of PRO has been found in 
multiple myeloma [198], breast cancer [193, 199], gastric cancer [200] and 
neuroblastoma [201]. PRO’s anti-cancer activity was attributed to its inhibition 
of the β2 adrenergic receptor, not the β1 subtype [201]. In humans, β-
adrenergic receptors are expressed in the urinary bladder. However, 
quantification of the respective receptor subtypes messenger ribonucleic acid 
(mRNA) – due to the difficulty in labelling and differentiating β-adrenergic 
receptor protein subtypes [202] – established that up to 97% of β-adrenergic 
receptors mRNA in the bladder belonged to the β3 subtype with only 1.5% and 
1.4% belonging to β1 and β2 subtypes respectively [203]. PRO has much lower 
affinity for β3 receptors as compared to β1 and β2 receptors [204]. Despite so, 
urothelial cancer cells are reported to have higher expression of VEGF than 
bladder epithelial cells [205] and bladder cancer cell line, T24 has been shown 
to respond to PRO inhibition [206-208]. Hence, the anti-cancer activity of PRO 
in bladder cancer will be further explored.  
 
2.2.4. Captopril 
 CAP is a drug belonging to a class called angiotensin-converting 
enzyme (ACE) inhibitors. ACE inhibitors work by inhibiting the conversion of 
angiotensin I to angiotensin II which is a potent vasoconstrictor. At the same 
time, it increases the amount of bradykinin by preventing its degradation [209]. 
These  eventually lead to vasodilation and a decrease in blood volume [210]. 
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Its main indications are, hypertension, heart failure and are also used to prevent 
kidney problems that are caused by hypertension or diabetes [211, 212]. As 
with PRO, there has been conflicting reports of whether ACE inhibitors could 
lead to reduced cancer risk and inhibit cancer growth, with some studies 
supportive of the notion [213-216] while others disagree [217-219].  
 Dysregulation of the renin–angiotensin system (RAS) can influence 
cancer progression. Angiotensin II, the active product of the RAS, was found 
to be involved in regulating cell growth, cell adhesion, metastasis [220, 221], 
inflammation and angiogenesis [222, 223], all of which are hallmarks of cancer 
[224]. In vitro and in vivo, ACE inhibitors are discovered to have potential in 
inhibiting lung cancer [225], leukaemia [226], breast cancer [227], renal cell 
carcinoma [228], bladder cancer [229] and gastric cancer [230], reducing 
tumour volume and metastasis. The effects observed are explained to be due 
to precise antagonism of RAS rather than due to antihypertensive effects 
indicating dysregulation of RAS during malignancy [222]. CAP was also found 
to have synergistic effects when used in combination with cyclophosphamide 
in lung carcinoma [231], with 5-fluorouracil in hepatocellular carcinoma [232].  
 Despite evidence showing that CAP has cytotoxic effects, one possible 
drawback of CAP as an anti-cancer drug is its immunomodulatory properties 
[233] and significantly, its ability to interfere with the activation of T cells [209]. 
This has resulted in CAP treatment promoting the growth of immunogenic 
tumours in immunocompetent hosts [234]. Since the fight against bladder 
cancer benefits from the activation of the immune system, this could present a 
disadvantage to the use of CAP in bladder cancer.   
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2.3. Materials and Methods 
2.3.1. Drugs 
 MMC was obtained from Santa Cruz Biotechnology (California, USA). 
MET was purchased from TCI Chemicals (Japan). SOM was a kind gift from 
Dr Bill Cham (Vanuatu Medical, Vanuatu). SON and SOD were obtained from 
Baoji Herbest Bio-Tech Co. Ltd (Shaanxi, China). All drugs were of analytical 
purity. Dimethyl sulfoxide (DMSO) was obtained from Sigma Aldrich (St. Louis, 
MO, USA) and 1 X phosphate buffered saline (PBS) was obtained from Vivantis 
(Selangor, Malaysia). All drugs except MET were dissolved in DMSO and MET 
was dissolved in 1 X PBS at pH 7.4.  
 
2.3.2. Cell Lines and Cultures 
 Bladder cancer cell lines, MGH, UMUC-3, J82, T24 and bladder 
epithelium cell line HUC-1 were a kind gift from Dr Ratha Mahendran (National 
University Hospital, Singapore). MGH, J82 and T24 cell lines were cultured in 
RPMI 1640 medium (Biowest, France) while UMUC-3 cell line was cultured in 
MEM medium (Gibco, NY, USA) and HUC-1 cell line was cultured in Ham’s 
F12 medium (Gibco, NY, USA). All cell culture media were supplemented with 
10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 50 U/mL penicillin 
G and 50 µg/mL streptomycin. The cells were grown in a humidified incubator, 
maintained at 37 °C with air containing 5% CO2.   
2.3.3. Cell Viability Assay 
 Cell viability was evaluated with the use of PrestoBlue® Cell Viability 
Reagent (Thermo Fisher Scientific Inc, MA, USA). The cells were counted and 
1 X 104 cells in 100 µL of media were seeded into each well in a 96-well 
microtiter plate (Corning, NY). The cells were then incubated for 24 hours. 
Following that, they were checked for confluency and the cells were treated 
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when they reach 80-90% confluence. The cell culture medium was replaced 
with 200 µL of fresh medium, supplemented with an increasing concentration 
of drug dissolved in DMSO. The concentration of DMSO in the medium was 
less than 0.1% to minimize the toxicity of DMSO to cells.  
 The cells were treated for 72 hours. The medium was removed and the 
cells were incubated with PrestoBlue® Cell Viability Reagent for 30 minutes. 
The plates were then read by Tecan infinite 200 Pro Microplate Reader 
(Switzerland) at a wavelength of 570 nm with 600 nm as the reference 
wavelength.  
 All absorbance readings were first corrected for background 
absorbance using blank wells with no cells. Survival was then calculated by 
taking the percentage of the absorbance relative to that of cell controls treated 
with vehicle. The half maximal inhibitory concentration (IC50) was calculated 
using a built-in non-linear regression model, sigmoidal dose-response (variable 
slope) from Graphpad (La Jolla, CA, USA) and was defined as the 
concentration of drug required to cause 50% of the cells to be no longer viable. 
 
2.3.4. Cell Viability Assay with Short Incubation 
 To mimic the intravesical chemotherapy conditions where MMC 
solution would be held within the bladder for an hour, cell viability assays were 
also performed for short drug treatment durations of one or three hours to study 
the effect of time on the cytotoxicity of the drug treatment. Drug treatment was 
performed with MMC and SOM against cell lines, HUC-1, MGH, UMUC-3 and 
T24. Similarly, as described in Section 2.3.3, cells were seeded and incubated 
for 24 hours to allow the cells to adhere. Following that, cells were treated for 
one or three hours. After which, the fresh medium without drug was 
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supplemented and the cell viability was determined using PrestoBlue® Cell 
Viability Reagent at 48 hours post-treatment.  
 
2.3.5. Selectivity Index 
 The selectivity index (SI) was calculated, according to earlier studies 
[235] as,  
𝑆𝐼 =
𝐼𝐶50 𝑜𝑓 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 𝑖𝑛 𝑏𝑙𝑎𝑑𝑑𝑒𝑟 𝑒𝑝𝑖𝑡ℎ𝑒𝑙𝑖𝑎𝑙 𝑐𝑒𝑙𝑙𝑠
𝐼𝐶50 𝑜𝑓 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 𝑖𝑛 𝑏𝑙𝑎𝑑𝑒𝑟 𝑐𝑎𝑛𝑐𝑒𝑟 𝑐𝑒𝑙𝑙𝑠
 
 A SI value of greater than one would indicate that the compound is selectively 
more toxic towards bladder cancer cells while a SI value of less than one 
indicates that the compound is more toxic towards bladder epithelial cells.  
 
2.4. Results  
 The cell cytotoxicity of MMC, SOM, SON, SOD and MET were 
evaluated in three cell lines, MGH, UMUC-3 and HUC-1. The cell cytotoxicity 
of SOM and MMC were further evaluated in another two bladder cancer cell 
lines, J82 and T24.  
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2.4.1. Mitomycin C was More Effective against Bladder Epithelial Cells 
than Bladder Cancer Cells 
 
 
Figure 8. Cell viability graph in log scale of MMC treatment on cell lines MGH, 
UMUC-3, J82, T24 and HUC-1 after 72 hours. At least triplicates were performed 
and values were given as mean ± standard error (SEM). 
 
 Bladder epithelial cells, HUC-1 was about five times more sensitive than 
bladder cancer cells, MGH, UMUC-3, J82 and T24 cells to MMC treatment, 
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2.4.2. Solamargine had Best Efficacy against Bladder Cancer Cells 
Amongst Glucoalkaloids 
 
Figure 9. Cell viability graph in log scale of SOM treatment on cell lines MGH, 
UMUC-3, J82, T24 and HUC-1 after 72 hours. At least triplicates were performed 
and values were given as mean ± SEM. 
 
 
Figure 10. Cell viability graph in log scale of SON treatment on cell lines MGH, 
UMUC-3 and HUC-1 after 72 hours. At least triplicates were performed and values 











































Figure 11. Cell viability graph in log scale of SOD treatment on cell lines MGH, 
UMUC-3 and HUC-1 after 72 hours. At least triplicates were performed and values 
were given as mean ± SEM. 
 
 From the cell viability assays of the glucoalkaloids, SOM and SON were 
the most potent amongst the three compounds (Figure 9 – 11). SOD had the 
mildest cytotoxic effects out of the three compounds and was more toxic 
towards the bladder epithelial cell line than the bladder cancer cells. The IC50 
values of SOD treatment of MGH and UMUC-3 bladder cancer cells were 4 
times and 3 times higher than that of IC50 value of SOD treatment of HUC-1 
cells (Figure 11). For SOM and SON, both drugs had shown cytotoxic effects 
towards both bladder cancer and epithelial cell lines. SOM performed best as 
it was relatively less toxic towards bladder epithelial cells while showing efficacy 
towards bladder cancer cells. For the treatment of SOM and SON, UMUC-3 
cells were shown to be most sensitive, with IC50 values three times lower than 
that of other cell lines. J82 and T24 cells were also treated with SOM and found 
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2.4.3. Metformin Inhibited Cell Proliferation of Bladder Cancer Cells 
 
Figure 12. Cell viability graph in log scale of MET treatment on cell lines MGH, 
UMUC-3 and HUC-1 after 72 hours. At least triplicates were performed and values 
were given as mean ± SEM. 
 
 Bladder cancer cells UMUC-3 were most sensitive to MET with an IC50 
value of 1.8 mM followed by MGH cells and bladder epithelial cells, HUC-1 with 
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2.4.4. Propranolol was Ineffective against Bladder Cancer Cells 
 
Figure 13. Cell viability graph in log scale of PRO treatment on cell lines MGH, 
UMUC-3 and HUC-1 after 72 hours. At least triplicates were performed and values 
were given as mean ± SEM. 
 
 PRO did not have any significant effect against UMUC-3 and MGH cell 
lines at concentrations of up to 200 µM. On the other hand, PRO demonstrated 
cytotoxic effects on bladder epithelial cells, HUC-1 cell line at concentrations 





















Exploration of New and Old Drugs for the Treatment of Bladder Cancer 
Page 32 
 
2.4.5. Captopril had No Cytotoxic Effects against Bladder Epithelial and 
Cancer Cells 
 
Figure 14. Cell viability graph in log scale of CAP treatment on cell lines MGH, 
UMUC-3 and HUC-1 after 72 hours. At least triplicates were performed and values 
were given as mean ± SEM. 
 
 Across all three cell lines, CAP had no cytotoxic effects at 
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2.4.6. Longer Drug Exposure Time Enhanced Drug Cytotoxicity 
 
Figure 15. Cell viability of various cell lines with MMC treatment in log scale for 
one or three hours followed by incubation for 48 hours 
 
 
Figure 16. Cell viability of various cell lines with SOM treatment in log scale for one 
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 The cell cytotoxicity of both drugs was dependent on the drug exposure 
time, with an increase in cell kill as drug exposure time increases. The cells 
were treated with MMC at concentration of up to 100 µM. As the concentration 
of MMC increases beyond 20 µM, there was no further increase in cell 
cytotoxicity and cell kill plateaus without reaching 100% cell kill. At 
concentrations of above 20 µM, drug incubation time was crucial in increasing 
the cell cytotoxicity of MMC, where drug treatment of 3 hours kills 10% more 
cells than drug treatment of an hour. On average, the cell survival after 3 hours 
of drug treatment was 20% (Figure 15).  
 On the other hand, cells were treated with SOM at concentrations up to 
25 µM. Likewise, longer drug treatment times result in increased cell 
cytotoxicity (Figure 16). Compared to MMC, the dose-response curve for SOM 
was steeper. For drug treatment of 3 hours, SOM at 25 µM was more 
efficacious than MMC at 100 µM.  
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2.4.7. Summary of IC50 Values and Selectivity Index 
 A summary of the IC50 values and SI obtained for each drug treatment 
were presented below (Table 2 and 3). 
Table 2. IC50 values of the various drug treatment for 72 hours against the five cell 
lines.   
Cell Line 
Drug Treatment 
MMC SOM SON SOD MET 
HUC-1 0.02 µM 9.5 µM 8.6 µM 11.1 µM 38.5 mM 
MGH 0.1 µM 9.5 µM 11.2 µM 40.5 µM 25.1 mM 
UMUC-3 0.1 µM 3.6 µM 3.46 µM 31.1 µM 1.8 mM 
J82 0.1 µM 8.3 µM    
T24 0.09 µM 9.2 µM    
 
Table 3. SI calculations of the various drug treatment in bladder epithelial cell line 
as compared to bladder cancer cell lines.  
Cell Line 
Drug Treatment 
MMC SOM SON SOD MET 
MGH 0.20 1.00 0.77 0.27 1.53 
UMUC-3 0.20 2.64 2.49 0.36 21.39 
J82 0.20 1.14    
T24 0.22 1.03    
 
2.5. Discussion 
 Bladder cancer is the 11th most common cancer in the world. Even 
though the incidence of bladder cancer has reduced, NMIBC remains the 
cancer that tops the lifetime treatment cost per patient as it has high incidence, 
recurrence and survival rates. Conventional intravesical chemotherapy has 
shown to be lower in efficacy compared to intravesical BCG, even though it 
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also has lower risks of side effects. This study hence, seeks to evaluate the 
efficacy of other potential chemotherapeutic agents, such as glucoalkaloids, 
MET, PRO and CAP.   
 MMC, which is a standard chemotherapeutic drug in bladder cancer 
was more 5 times more cytotoxic to bladder epithelial cells than bladder cancer 
cells even though it was the most cytotoxic compound out of all the compounds 
tested.  
 Out of the three glucoalkaloids, SOM and SON had comparable efficacy 
while SOD had mild cytotoxic effects. Even though it was reported that SOM 
and SON have specific efficacy against cancer cells through its ability to bind 
preferentially to them [130], both compounds did not demonstrate selective 
efficacy against cancer cells in this study. Bladder epithelial cell line, HUC-1 
was found to have comparable IC50 values to that of other bladder cancer cells. 
Only UMUC-3 was shown to be more sensitive to both drugs. Further testing 
was performed on J82 and T24 cell lines in an effort to identify potential 
pathways that might render UMUC-3 to be more sensitive to SOM and SON. 
UMUC-3 was determined to be similar to J82 and T24 through a 
complementary DNA (cDNA) microarray [28] according to the hierarchical 
clustering of overexpressed genes. Another study also found UMUC-3 to be 
similar to J82 based on mouse double minute 2 (MDM2), retinoblastoma 
protein (Rb) and E-cadherin staining [236]. However, J82 and T24 cell lines 
were not as sensitive to SOM as UMUC-3 cells. 
 MET was shown to be more efficacious to bladder cancer cells than 
bladder epithelial cells. In particular, UMUC-3 was most sensitive to the effects 
of MET. These cells have an IC50 value of 1.8 mM followed by MGH and bladder 
epithelial cells, HUC-1 with IC50 values of 25.1 mM and 38.5 mM respectively. 
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The IC50 values obtained concur with earlier studies, with cell viability 
experiments performed in bladder cancer cell lines having IC50 values in the 
mM range as well [237, 238]. Recently, it has been shown that cells that are 
more sensitive to MET are defective in the regulation of oxidative 
phosphorylation [167, 239]. These cells were also more sensitive to low 
glucose conditions [240]. The large disparity in the sensitivity of UMUC-3 to 
MET as compared to other cell lines could indicate that UMUC-3 may be 
defective in their ability to engage in aerobic glycolysis. Further experiments 
would be necessary to confirm this theory.  
 The high IC50 value makes MET unsuitable for clinical therapeutic 
applications. Hence, a viable alternative strategy would be to administer MET 
in combination with other chemotherapeutic drugs achieving synergism, thus 
lowering the dose required. Wang and Wu have demonstrated that the use of 
cisplatin in combination with MET is synergistic against bladder carcinoma in 
vitro and in vivo [241].  
 PRO [193, 197-201] and CAP [225-230] both had no cytotoxic effects 
against bladder cancer cells despite many reports of anti-cancer activity. Non-
response in both drugs indicates that these drugs are not suitable as 
chemotherapeutic agents in bladder cancer treatment. It is hypothesised that 
bladder cancer cells might lack the β2 adrenergic receptor [201] that is 
necessary for PRO to exert its anti-cancer effects. As for CAP, the lack of 
cytotoxic effects against bladder cancer cells further endorse the notion that 
RAS signalling can be complex, dependent on context, thus making outcomes 
difficult to predict [222].  
 Cell viability assays with short treatment durations emphasized the 
importance of drug exposure time in influencing the cell cytotoxicity of the drug. 
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Even though the current dosage of MMC in intravesical chemotherapy is 6 mM, 
the efficacy of MMC plateaus beyond 20 µM, leading to potential future 
problems of recurrence and progression as an average of 20% of bladder 
cancer cells survive treatment. In this case, SOM might prove to be a better 
therapeutic agent, being able to cause nearly 100% cell death. Yet, the narrow 
therapeutic window of SOM might limit its therapeutic use. An alternative would 
be to improve the formulation of MMC, thereby allowing the drug to be retained 
in the bladder for an extended period of time at high concentration. Both 
compounds were equally non-selective towards cancer cells as compared to 
normal bladder cells.  
  
2.6. Conclusion 
 This study compared the efficacy of six compounds against the 
standard chemotherapeutic drug, MMC where three compounds are 
glucoalkaloids, SOM, SON and SOD and the other three compounds are FDA-
approved drugs, MET, PRO and CAP.  Of all six compounds evaluated against 
MMC, SOM performed best, being most potent while offering some degree of 
selectivity. PRO and CAP had no cytotoxic effects against bladder cancer cells. 
MET, while being potent only at high mM concentrations, was found to be more 
potent towards bladder cancer cells than bladder epithelial cells.    
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CHAPTER 3: EXPLORATION OF SYNERGISM BETWEEN 
MITOMYCIN C, SOLAMARGINE AND METFORMIN 
3.1. Summary 
 In this chapter, the drug combinations: MMC and MET, MMC and SOM, 
SOM and MET were evaluated for synergism in bladder cancer cell lines, MGH 
and UMUC-3 as well as bladder epithelium cell line, HUC-1. The combination 
of MMC and MET was found to be antagonistic while MMC and SOM had 
limited synergism against bladder cancer cells and co-treatment of SOM and 
MET was synergistic for UMUC-3 cells. This study cautions against using MMC 
and MET in diabetic patients with bladder cancer and further mechanistic 
studies would be necessary to identify molecular targets of the drug 
combinations in order to better predict the outcome of combination treatment.  
 
3.2. Introduction 
 Bladder cancer is the 11th most common cancer in the world [1] while in 
Singapore, bladder cancer is the 12th most common cancer [7]. Even though it 
has lower incidence rates, bladder cancer has the highest lifetime treatment 
cost per patient amongst all cancers [9], which is attributed to the cancer’s high 
incidence, recurrence and survival rates. 
 In bladder cancer, MMC is most commonly used for intravesical 
chemotherapy [90, 112]. By undergoing reduction, MMC is converted to a 
highly reactive alkylating agent [114] that goes on to inhibit DNA replication 
through covalently crosslinking of DNA strands [90]. MMC also inhibits 
thioredoxin reductase and through that, causing cytotoxicity [117]. However, 
despite being the drug of choice for intravesical chemotherapy, it is inferior in 
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preventing recurrence and has lower complete response rates as compared to 
intravesical BCG [64, 65, 70, 72].   
 Administering drugs in combination thus offers a solution to improve the 
efficacy and outcome of intravesical chemotherapy. With synergistic drug 
combinations, patients can benefit with higher therapeutic efficacy, decreased 
dose yet maintaining same efficacy, thereby reducing toxicities and cost. It can 
also delay the onset of drug resistance and provide selective synergism against 
target as compared to host, thereby increasing therapeutic index [242].  
 Synergistic drug combinations can arise due to the anti-counteractive 
actions, complementary actions or facilitating actions of the drug combined 
[243]. To evaluate synergism in drug combinations, the median-effect equation 
from Chou-Talalay is used. The median effect equation, which is derived from 
four basic equations: Michaelis-Menten equation, Hill equation, Henderson-
Hasselbalch equation and Scatchard equation [242] allows a quantitative 
assessment of the efficacy of drug combination through the use of the 
combination index (Figure 17).  
 
 
Figure 17. Illustration of the derivatization of the median-effect equation [242].  
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 MET brings about anti-cancer effects by reducing the amount of insulin 
and circulating glucose [149, 150], causing the stimulation of the AMPK 
pathway [158, 159], thus reducing protein synthesis and lower proliferation in 
cancer cells [162, 163]. MET is also able to act on the mitochondria, bringing 
about reduced cellular respiration [168, 169] and it is hypothesised that the 
decreased efficiency of energy metabolism causes toxicity for tumour cells 
[167]. It can also induce cell death under low glucose and low oxygen 
conditions by reducing the activation of HIF-1 under hypoxic conditions [169]. 
On the other hand, the most promising glucoalkaloid, SOM, is able to induce 
apoptosis through the activation of p38 MAPK [119].  
 Recent studies have shown that the co-administration of MET and anti-
cancer drugs with synergistic effects. In these studies, MET has been co-
administered with gefitinib in non-small cell lung cancer [244], with simvastatin 
in prostate cancer [245], with cisplatin in bladder cancer [241], lung cancer [246] 
and liver cancer [247] producing synergistic effects. In breast cancer, MET and 
mTOR inhibitor have also been shown to sensitize cancer cells to carboplatin, 
doxorubicin and paclitaxel treatment [248]. Aside from higher efficacy, one 
study has demonstrated higher complete response rates in patients receiving 
MET and neoadjuvant chemotherapy simultaneously in breast cancer [249].  
 The drug combinations of MMC and MET, MMC and SOM, SOM and 
MET have not been evaluated previously. Since all three drugs have different 
mechanism of action, the above-mentioned drug combinations will be 
evaluated for efficacy and synergism to assess their potential in improving 
current therapeutics.  
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3.3. Materials and Methods 
3.3.1. Drugs 
 MMC was obtained from Santa Cruz Biotechnology (California, USA). 
MET was purchased from TCI Chemicals (Japan). SOM was a kind gift from 
Dr Bill Cham (Vanuatu Medical, Vanuatu). All drugs were of analytical purity. 
DMSO was obtained from Sigma Aldrich (St. Louis, MO, USA) and 1 X PBS 
was obtained from Vivantis (Selangor, Malaysia). MMC and SOM were 
dissolved in DMSO while MET was dissolved in 1 X PBS at pH 7.4.  
 
3.3.2. Cell Lines and Cultures 
 Bladder cancer cell lines, MGH, UMUC-3 and bladder epithelium cell 
line HUC-1 were a kind gift from Dr Ratha Mahendran (National University 
Hospital, Singapore). MGH cell line was cultured in RPMI 1640 medium 
(Biowest, France) while UMUC-3 cell line was cultured in MEM medium (Gibco, 
NY, USA) and HUC-1 cell line was cultured in Ham’s F12 medium (Gibco, NY, 
USA). All cell culture media were supplemented with 10% heat-inactivated fetal 
bovine serum, 2 mM L-glutamine, 50 U/mL penicillin G and 50 µg/mL 
streptomycin. The cells were grown in a humidified incubator, maintained at 
37 °C with air containing 5% CO2.   
 
3.3.3. Cell Viability Synergism Assay 
 The cells were treated based on IC50 values obtained in Chapter 2 
(Table 2). Briefly, 1 X 104 cells were seeded into each well in a 96-well microtiter 
plate (Corning, NY). After 24 hours of incubation, the cells were treated with 
200 µL of fresh medium supplemented with varying concentration of the two 
drugs. Likewise, the concentration of DMSO in the medium did not exceed 0.1% 
to minimize the toxicity of DMSO to cells. 
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 The cells were treated with a combination of the two drugs at a constant 
combination ratio. The first column of wells would contain the two drugs to be 
tested, both at four times the IC50 concentration. A series of two-fold serial 
dilutions was then performed such that the second column of wells would 
contain drug at two times IC50 concentration, one times IC50 concentration and 
so on (Figure 18).  
 
Figure 18. Layout of the 96-well plate for combination treatment dose. x was the 
IC50 concentration of drug. For example, in well B2, the cells will be treated with 4x 
of Drug A and 4x of Drug B. 
 
 The cells were treated for 72 hours, following which, the medium was 
removed and the survival of the cells was evaluated with PrestoBlue® Cell 
Viability Reagent as in Section 2.3.3.  
 
3.3.4. Drug Synergism Calculation 
 The combination index (CI) was then calculated according to Chou-
Talalay [242] where there is synergism when CI < 1, additive effect when CI = 
1 and antagonism when CI > 1. According to Chou-Talalay’s median effect 
equation [242], for each pair of drug treatment, from the cell viability data, the 
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median-effect plot was plotted to obtain the value of 𝑚. The median-effect 




] = 𝑚 log 𝐷 − 𝑚 log 𝐷𝑚 




− 1] = 𝑚 log 𝐷 − 𝑚 log 𝐷𝑚 
Where 𝑓𝑎 is the fraction of cells affected by the treatment, 𝑓𝑢 is the fraction of 
cells unaffected by the treatment, 𝑚 is the slope, 𝐷 is the dose and 𝐷𝑚 is the 
median-effect dose.  
 Graphs of log [
1
𝑓𝑢
− 1]  against log 𝐷  were plotted for the drug 
combination treatment as well as each individual drug treatment. Values of 𝑚 
and 𝐷𝑚 can then be obtained from the slope and y-intercept of the straight line 
plot respectively. With these values, 𝐷𝑥  can be calculated for a range of 𝑓𝑎 
values of 0 to 1 for drugs in combination and for the two individual drugs using 
the equation below:   







Where 𝐷𝑥 is the dose required to achieve 𝑥% inhibition in combination.  
 𝐷𝑥  was separated into 𝐷1  and 𝐷2  which were the doses for the two 
drugs individually based on the proportion of the concentration of the two drugs 
during treatment. Together with the previously obtained values of (𝐷𝑥)1 and 
(𝐷𝑥)2, the CI can be calculated according to the equation below for 𝑓𝑎 of values 
0 to 1.  













Where (𝐷𝑥)1and (𝐷𝑥)2 is the dose required to achieve 𝑥% inhibition when used 
alone.  
 The CI plot was thus obtained by plotting CI against 𝑓𝑎, also known as 
fractional effect (Fa). Figures 20, 22 and 24 showed the CI plot of MMC and 
MET, MMC and SOM, SOM and MET combination treatments.  
 
3.4. Results  
 The effects of combination treatment of two of the three drugs, SOM, 
MMC and MET on bladder cancer cell line, MGH and UMUC-3 and bladder 
epithelium cell line, HUC-1 were evaluated. 
 
3.4.1. Co-treatment of Mitomycin C and Metformin was Antagonistic 
 
Figure 19. Cell viability graph of MMC and MET combination treatment on cell lines 
MGH, UMUC-3 and HUC-1. Triplicates were performed and values were given as 
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Figure 20. CI against Fa plot for MMC and MET combination treatment on cell 
lines MGH, UMUC-3 and HUC-1. CI = 1 was plotted as a dotted line, indicating 
synergism when CI < 1, additive effect when CI = 1 and antagonism when CI > 1. 
 
 For all three cell lines, the treatment of MMC and MET was performed 
at fixed IC50 ratios of (1:2.5×105), (1:1.75×104) and (1:1.88×106) for MGH, 
UMUC-3 and HUC-1 cells respectively. Drug treatment inhibited cell 
proliferation and viability in a concentration-dependent manner (Figure 19). 
However, despite so, when both drugs were dosed at IC50 concentration, there 
was no improvement in efficacy, with both bladder cancer cell lines, MGH and 
UMUC-3 having a survival of about 50% while bladder epithelial cell line, HUC-
1 having a survival of 32%. Calculating the CI, we observed that the addition of 
MET suppressed the cytotoxicity of MMC, resulting in an antagonistic drug 
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3.4.2. Co-treatment of Mitomycin C and Solamargine had Limited 
Synergism against Bladder Cancer Cells 
 
Figure 21. Cell viability graph of MMC and SOM combination treatment on cell 
lines MGH, UMUC-3 and HUC-1. Triplicates were performed and values were 
given as mean ± SEM. x was the IC50 of the drugs dosed.  
 
 
Figure 22. CI against Fa plot for MMC and SOM combination treatment on cell 
lines MGH, UMUC-3 and HUC-1. CI = 1 was plotted as a dotted line, indicating 
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 Likewise, for combination treatment of MMC and SOM, drugs were 
dosed at a fixed IC50 ratio of (1:100), (1:37) and (1:500) for MGH, UMUC-3 and 
HUC-1 cells respectively. Cell proliferation and viability were inhibited in a 
concentration-dependent manner. When both drugs were dosed at IC50 
concentration, it was observed that the cell viability of the bladder cancer cells 
was reduced more than that of the bladder epithelial cells (Figure 21). The 
combination treatment was synergistic when Fa was more than 0.6 for UMUC-
3 and 0.7 for MGH cells. The drug combination was antagonistic for HUC-1 
cells (Figure 22).   
 
3.4.3. Co-treatment of Solamargine and Metformin was Synergistic 
against UMUC-3 Cells 
 
Figure 23. Cell viability graph of SOM and MET combination treatment on cell lines 
MGH, UMUC-3 and HUC-1. Triplicates were performed and values were given as 
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Figure 24. CI against Fa plot for SOM and MET combination treatment on cell lines 
MGH, UMUC-3 and HUC-1. CI = 1 was plotted as a dotted line, indicating 
synergism when CI < 1, additive effect when CI = 1 and antagonism when CI > 1. 
 
 The combination treatment of SOM and MET was dosed at a fixed IC50 
ratio of (1:2500), (1:467) and (1:3750) for MGH, UMUC-3 and HUC-1 cells 
respectively. Drug treatment inhibited cell proliferation and viability in a 
concentration-dependent manner. At the IC50 concentration for both drugs, the 
treatment resulted in a survival of about 40% for UMUC-3 cells. and 10% for 
both MGH and HUC-1 cells (Figure 23). However, after calculating CI, 
synergism was observed for UMUC-3 cells when Fa was greater than 0.4 while 
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3.4.4. Summary of Combination Indices 
Table 4. CIs for the various drug combinations in MGH, UMUC-3 and HUC-1 cells
Cell 
line 





























0.1 5.05 4.85 11.54 4.72 5.79 2.91 2.08 6.93 2.41 
0.2 3.66 3.01 6.56 3.23 3.03 1.61 1.81 4.83 1.98 
0.3 2.98 2.23 4.58 2.53 2.02 1.12 1.65 3.83 1.75 
0.4 2.52 1.76 3.45 2.09 1.47 0.84 1.53 3.19 1.58 
0.5 2.17 1.42 2.68 1.75 1.10 0.65 1.43 2.70 1.44 
0.6 1.87 1.16 2.09 1.48 0.83 0.50 1.34 2.29 1.31 
0.7 1.60 0.93 1.62 1.23 0.62 0.38 1.25 1.93 1.19 
0.8 1.32 0.72 1.19 0.99 0.43 0.28 1.14 1.57 1.06 
0.9 1.00 0.49 0.77 0.72 0.26 0.18 1.00 1.16 0.89 
 
Table 5. Summary of the Fa of the various drug combinations.  
Cell Line Treatment Synergism observed at Fa = ? 
HUC-1 
MMC + MET No 
MMC + SOM No 
SOM + MET Yes, at Fa ≥ 0.9 
UMUC-3 
MMC + MET Yes, at Fa ≥ 0.8 
MMC + SOM Yes, at Fa ≥ 0.6 
SOM + MET Yes, at Fa ≥ 0.4 
MGH 
MMC + MET No 
MMC + SOM Yes, at Fa ≥ 0.7 
SOM + MET Yes, at Fa ≥ 0.9 
 




 Bladder cancer, despite lowering incidence rates, has the highest 
lifetime treatment cost per patient amongst all cancers [9] and this is due to the 
cancer’s high incidence, recurrence and survival rates. To improve the efficacy 
of intravesical chemotherapy, reduce recurrence and lower the risk of side 
effects, administration of chemotherapeutic drugs in combination was explored.  
 Several studies have shown that the co-administration of MET and anti-
cancer drugs have synergistic effects against cancer cells, enhancing 
treatment efficacy [241, 244-248]. However, in our study, in vitro drug 
combination of MMC and MET against bladder cancer have not offered 
additional advantages as co-treatment was largely antagonistic. This is despite 
both drugs inducing cell death through different molecular mechanisms.   
 While studies largely report the synergistic interactions between anti-
cancer agents and MET, antagonistic interactions have also been reported in 
a few studies. Cisplatin, another chemotherapeutic drug that similarly forms 
DNA adducts like MMC [250], has shown differential effects when used in 
combination with MET [251]. Whether the combination is synergistic or 
antagonistic is likely to be dependent on the type of cancer as well as the 
cancer cell type [251]. In gastric cancer cell line, cisplatin and MET treatment 
was found to be antagonistic due to the upregulation of survivin, mTOR and 
protein kinase B (Akt) [252]. Another study found that the AMPK-independent 
upregulation of Akt leads to the survival of the cancer cells [251]. The 
upregulation of Akt is anti-apoptotic as it inhibits pro-apoptotic proteins, 
caspases and impedes the release of cytochrome c [253]. Since MET was 
unable to sensitize bladder cancer cells to MMC treatment, care must be taken 
if both drugs are co-prescribed for bladder cancer patients with type 2 diabetes.  
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 In vitro treatment with MMC and SOM on the other hand, demonstrated 
limited synergism against bladder cancer cells, MGH and UMUC-3, while being 
antagonistic against bladder epithelial cells, HUC-1. This drug combination 
could present therapeutic advantages as it was able to selectively sensitize 
bladder cancer cells, increasing efficacy and reducing toxicity to normal 
epithelial cells. Further work to deduce the cellular mechanism of action of SOM 
is necessary to further enhance the synergism observed while maintaining 
antagonistic interactions against bladder epithelial cells.  
 Lastly, combined drug treatment of SOM and MET demonstrated 
significant synergism against bladder cancer cell UMUC-3, while minor 
synergism was observed in MGH and HUC-1 cells. Further work to understand 
the differences in pathway aberrations between UMUC-3 and MGH cells will 
allow a better understanding of how the drug combination leads to cell death 
and the differential sensitivity between the two cancer cell lines.  
 The outcome of drug combination treatment cannot be easily predicted 
in cancer since cancer cells are rarely homogeneous, with wide variety of 
pathway aberrations and protein mutations present. As shown by Franziska et 
al., in vitro treatment using a combination of vemurafenib and MET against 19 
melanoma cell lines can yield differential effects, even when cells have the 
same driver mutation: v-raf murine sarcoma viral oncogene homolog B1 
(BRAFV600E) or neuroblastoma RAS (NRASQ61). Furthermore, no predictive 
markers could be identified to predict whether the combination would be 
synergistic or antagonistic [254]. In another study optimizing drug combinations 
against eight bladder cancer cell lines, varying chemoresistance was observed 
when these cell lines were treated with six chemotherapeutic drugs. The 
optimised drug combination was noted to be more capable than the increased 
dose of single drug component in killing the wide diversity of bladder cancer 
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cells. Subsequently, this was explained by the signalling pathways triggered by 
the drug combination [255]. Therefore, a more comprehensive understanding 
of the cellular mechanisms behind every drug combination is necessary.  
 
3.6. Conclusion 
 This study demonstrated the ability of MET to inhibit the cytotoxicity of 
MMC, suggesting that MET is not suitable to be co-administered with MMC to 
improve the efficacy of intravesical chemotherapy. In addition, caution should 
be taken when prescribing both drugs in bladder cancer patients who also 
suffer from type 2 diabetes. As for combination drug treatment of MMC and 
SOM, synergism was observed against bladder cancer cells but the 
combination can be further optimised to achieve higher efficacy with a better 
understanding of cellular mechanisms of action. As for SOM and MET, further 
investigation to characterize the cell lines will enable us to understand the 
reasons leading to differential sensitivity to the combination drug treatment.  
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CHAPTER 4: IDENTIFICATION OF PATHWAYS 
EFFECTED IN SOLAMARGINE TREATMENT 
4.1. Summary 
 In this chapter, microarray analysis was performed on MGH and UMUC-
3 cells, untreated and treated with SOM for 3 hours with the aim of identifying 
differences between the two cell lines as well as to observe the molecular 
pathways affected by SOM treatment. Western blot of MAPK pathways and 
enzyme-linked immunosorbent assay (ELISA) of cytokines were performed to 
validate the microarray results. SOM was found to increase the 
phosphorylation of MAPK proteins in MGH cells but not in UMUC-3 cells. 
Constitutive secretion of IL-6, IL-8 and GM-CSF were also found in MGH cells. 
SOM treatment led to a decrease in IL-8 secretion.   
 
4.2. Introduction 
 Bladder cancer is the 11th most common cancer in the world [1] while in 
Singapore, bladder cancer is the 12th most common cancer [7]. Bladder cancer 
has the highest lifetime treatment cost per patient amongst all cancers [9], 
despite its lower incidence rates. This is due to the cancer’s high incidence, 
recurrence and survival rates. Hence, more effective treatment is necessary to 
reduce the economic cost of bladder cancer.  
 In Chapter 2 and 3, cell cytotoxicity experiments and drug synergism 
studies have been performed on bladder cancer cells. However, much is not 
known about the molecular mechanism of action of SOM. In this Chapter, we 
will explore and uncover the molecular mechanism of action of SOM through 
the use of microarray and other validation experimental assays.  
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 Microarray was developed in 1988 with its first application in 1995 [256], 
leading to the earliest paper on microarray evaluating gene expression by 
Schena et al. [257]. The microarray relies on the hybridization of 
complementary strands of nucleic acids to the synthetic DNA on the chip and 
subsequently, quantification of gene expression through fluorescence [258]. 
The DNA samples would be labelled with fluorescent dyes before the 
hybridization to allow for its detection later [259]. Since 1995, the technology 
has since been used for gene expression profiling and identification of single-
nucleotide polymorphisms, mutations, biomarkers in cancer [260], determine 
transcription factor binding sites [261] and as diagnostics [262]. Microarray has 
also been used in a variety of disease conditions.  
 Microarrays can also be powerful tools in the investigation of the 
molecular mechanism of action behind the biological activity of the drug [263]. 
Aside from that, they may also identify genes that can serve as a predictor 
biomarker for response [264] and used to predict the compound’s toxicity by 
observing the gene expression of cytochrome P450 detoxifying enzymes [265, 
266].  
 Despite its many applications, microarrays do have its limitations. The 
small amount of ribonucleic acid (RNA) used for the analysis renders 
microarray of tissue samples inaccurate since generally, tissue samples 
consist of a mixture of cell types [267]. This problem is further complicated in 
cancer tissues since cancer cells can be highly heterogeneous, even within the 
same tumour. mRNA quality is also important in obtaining accurate microarray 
analyses as mRNA can degrade very easily [267, 268]. Lastly, there has been 
difficulty in replicating microarray results and comparing microarray results 
across laboratories, impeding its clinical use [267, 269, 270].   
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 Hence, to investigate the pathway alterations resulting from SOM 
treatment, microarray was performed to identify the genes and cellular 
pathways that were affected by the SOM treatment. Comparison was also 
made between untreated MGH and UMUC-3 cells to identify differences in the 
two cell lines that could lead to a difference in sensitivity to SOM treatment.  
 
4.3. Materials and Methods 
4.3.1. Drugs  
 SOM was a kind gift from Dr Bill Cham (Vanuatu Medical, Vanuatu). 
The drug was of analytical purity. DMSO was obtained from Sigma Aldrich (St. 
Louis, MO, USA).  
 
4.3.2. Cell Lines and Cultures 
 Bladder cancer cell lines, MGH and UMUC-3 were a kind gift from Dr 
Ratha Mahendran (National University Hospital, Singapore). MGH cell line was 
cultured in RPMI 1640 medium (Biowest, France) while UMUC-3 cell line was 
cultured in MEM medium (Gibco, NY, USA). All cell culture media were 
supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 
50 U/mL penicillin G and 50 µg/mL streptomycin. The cells were grown in a 
humidified incubator, maintained at 37 °C with air containing 5% CO2.   
 
4.3.3. RNA Extraction for Illumina Microarray 
 For each cell line, 1 X 106 cells in 10 mL of media were seeded into 
each T-25 flask (Corning, NY). The cells were then incubated for 24 hours. 
Following that, they were checked for confluency and the cells were treated 
when they reach 80-90% confluence. The medium was then removed and 
replaced with fresh medium supplemented with either vehicle control or SOM 
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at the IC50 concentration (72 hours) of the respective cell lines as determined 
previously. The vehicle was DMSO at 0.1% in medium to minimize toxicity to 
cells. For each cell line, triplicates were prepared for each treatment. The cells 
were treated for 3 hours.  
 RNA extraction was performed using Direct-zol™ RNA MiniPrep (Zymo 
Research, CA, USA). Briefly, after treatment, the cells were washed with 1 X 
PBS. 500 µL of TRI Reagent was added to the flask. After lysis, an equal 
amount of ethanol (Merck, NJ, USA) was added and mixed thoroughly. The 
mixture was transferred into a Zymo-Spin™ IIC Column in a collection tube and 
centrifuged at 10,000 rpm for 30 seconds. The flow through was discarded and 
the column was transferred onto a new collection tube. 400 µL of Direct-zol™ 
RNA PreWash was then added to the column and centrifuged under the same 
conditions twice, discarding the flow through after each centrifugation. Add 700 
µL of RNA Wash Buffer and centrifuge at 10,000 rpm for 2 minutes. The column 
was transferred onto a RNase-free tube. The RNA was eluted by adding 50 µL 
of RNase-Free Water to the column and centrifuged at 10,000 rpm for 30 
seconds. The RNA extracted was stored at -80 °C.  
 The RNA extracted was checked for quality using Nanodrop 8000 
(Thermo Fisher Scientific, MA, USA). The total RNA quantity should be at least 
2 µg while OD260/280, OD260/230 should be at least 1.7. 28S/18S rRNA ratio 
should be at least 1.7 as well. The extracted RNA was stored under ethanol 
precipitation condition before sending for analysis. 5 µL of 3 M of sodium 
acetate of pH 7 – 8 was added to the 50 µL of RNA solution and mixed gently. 
110 µL of 100% ethanol was then added to the solution, mixed well gently and 
stored at -20 °C.  
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4.3.4. Illumina Microarray 
 Microarray was performed using the Illumina HumanHT-12 v4 
Expression BeadChip (Illumina, Inc., San Diego, CA). Each BeadChip allows 
for the analysis of 12 samples, targeting a total of 47,000 probes from the 
National Center for Biotechnology Information Reference Sequence (NCBI) 
RefSeq Release 38 [271]. Briefly, biotinylated cDNA was synthesised from 0.55 
µg total RNA using the Illumina TotalPrep RNA Amplification Kit (Ambion, 
Austin, TX). The cDNA was then quantitated and fragmented before 0.75 µg of 
cDNA was hybridised to the Illumina Expression Beadchip according to 
manufacturer’s instructions. The arrays were read and scanned using the 
Illumina Bead Array Reader Confocal Scanner. Data analysis was performed 
using Illumina GenomeStudio v2011.1 (Gene Expression Module v1.9.0). 
Database for Annotation, Visualization and Integrated Discovery (DAVID) and 
Partek Genomics Suite 6.6 (Partek, St. Louis, USA) was also used to further 
interpret the microarray data and generate pathway maps.  
  
4.3.5. Protein Extraction for Western Blot 
 For western blot, 3 X 105 cells in 2 mL of media were seeded into each 
well in a 6-well plate. The cells were then incubated for 24 hours. Post-
incubation, the cells were treated at IC50 concentration and incubated for 2, 6 
and 24 hours. Following which, the cells were washed with ice-cold 1 X PBS 
and lysed in 50 µL of radioimmunoprecipitation assay (RIPA) buffer 
supplemented with Protease Inhibitor Cocktail Set III (Calbiochem, CA, USA) 
and PhosSTOP™ (Roche, Basel, Switzerland) according to manufacturer’s 
instructions. The cells were incubated with RIPA buffer for 10 minutes at 4 °C 
and scrapped down using a cell scrapper. The protein lysates were collected 
in a 1.5 mL microcentrifuge tube and spun down at 10,000 g for 10 minutes at 
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4 °C. The supernatant was then transferred to another microcentrifuge tube 
and frozen down at -20 °C.   
 
4.3.6. Western Blot 
 Western blot was performed to detect the level of protein and 
phosphorylation of p38 MAPK, p-p38 MAPK, ERK1/2, p-ERK1/2, Jun N-
terminal kinase (JNK) 2 and p-Stress-activated protein kinases / Jun amino-
terminal kinases (SAPK/JNK). Primary antibodies against all the above-
mentioned proteins were from Cell Signalling Technology (Beverly, MA, USA) 
and were a kind gift from Dr Wang Ling-Zhi (National University Singapore, 
Singapore). Monoclonal anti-β-actin antibody (Sigma Aldrich, St. Louis, MO, 
USA) was used as a loading control. Two secondary antibodies were used. 
Anti-rabbit horseradish peroxidase (HRP) conjugate was obtained from Cell 
Signalling Technology (Beverly, MA, USA), while Amersham™ anti-mouse 
HRP conjugate was obtained from GE Healthcare (Little Chalfont, UK).   
 Mini-PROTEAN Tetra Cell System from Bio-Rad (CA, USA) was used 
for the protein electrophoresis and blotting. 15% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) resolving gel was cast using 
the casting stand and clamps and given an hour to polymerize. Following which, 
the stacking gel was added and the comb was inserted. The stacking gel was 
allowed to polymerize. The casting plates were assembled onto the electrode 
assembly and placed in the tank. Running buffer was added and the combs 
were removed. Before loading the samples, the protein concentration of the 
cell lysates was determined using BCA Protein Assay Kit (Thermo Fisher 
Scientific, MA, USA) and 25 µg of protein was loaded into each well. The 
protein ladder used was Spectra™ Multicolor Broad Range Protein Ladder 
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(Thermo Fisher Scientific, MA, USA). The gel was run at 100 V for two hours 
or until the sample dye reaches the end of the gel.  
 For the protein transfer, the Mini Trans-Blot Module (Bio-Rad, CA) was 
used. Nitrocellulose membrane (Bio-Rad, CA), filter paper and fiber pad were 
first soaked in cold transfer buffer. The stacking gel was removed and the 
transfer cassette was assembled such that the proteins on the gel would be 
transferred onto the membrane after blotting. The transfer cassette was then 
placed into the transfer module. Transfer buffer was added and the transfer 
was done at 130 V, for one and a half hours at 4 °C. Ponceau S solution (Sigma 
Aldrich, St. Louis, MO, USA) was used to visualize the proteins after the 
transfer.  
 The blot was incubated in 5% Anlene low-fat milk (Fonterra, NZ) 
dissolved in a mixture of Tris-Buffered Saline and Tween 20 (TBST) for 60 
minutes to block the blot. After blocking, the blot was incubated in primary 
antibody at 4 °C, overnight. The primary antibody was diluted in a solution of 
5% bovine serum albumin (BSA) Fraction V (BDH Chemicals, England, UK) in 
TBST, according to the dilution specified by the manufacturer. After overnight 
incubation, the blot was washed three times for 10 minutes then incubated in 
secondary antibody diluted in 1% milk in TBST for an hour at room temperature. 
The blot was washed three times before incubating in SuperSignal™ West Pico 
Chemiluminescent Substrate (Thermo Fisher Scientific, MA, USA) for one 
minute for signal development. CL-XPosure Film (Thermo Fisher Scientific, MA, 
USA) and film developer (Konica Minolta, Japan) were used to image the 
chemiluminescent signal on the blot. Quantification of the bands was 
performed using ImageJ software.  
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4.3.7. Cytokines Analysis 
 According to the Illumina Microarray results, several cytokines were 
observed to vary in expression levels before and after treatment in MGH cell 
line and between untreated MGH and UMUC-3 cell lines. Cytokines that were 
observed to vary before and after treatment in the MGH cell line were IL-1, IL-
1β and IL-6. On the other hand, between MGH and UMUC-3 cell lines, 
difference in expression were found in IL-1β, IL-6, IL-8, IL-15 and tumour 
necrosis factor alpha (TNF-α). Hence, the cytokines produced by MGH and 
UMUC-3 cell lines were analysed using the Human Inflammatory Cytokines 
Multi-Analyte ELISArray Kit (Qiagen, Venlo, Netherlands). A total of 12 
cytokines were analysed including, IL-1A, IL-1B, IL-2, IL-4, IL-6, IL-8, IL-10, IL-
12, IL-17A, interferon gamma (IFN-γ), TNF-α, granulocyte macrophage colony-
stimulating factor (GM-CSF).  
 MGH and UMUC-3 cells were seeded into a 12-well plate with 1.5 X 106 
cells in 1 mL of media per well. The cells were then incubated for 24 hours. 
After incubation, the cells were treated with fresh media supplemented with 
SOM dissolved in DMSO at IC50 concentration for 3 hours in line with what was 
performed for the microarray. For the control, cells were treated with fresh 
media supplemented with DMSO at 0.1% concentration. The supernatant was 
collected, stored at -20 °C and centrifuged at 10,000 g for 10 minutes at 4 °C 
before loading onto the ELISArray plate. Cell lysate was collected and protein 
concentration was quantified in the same manner as mentioned in Section 4.3.5.  
 Briefly, all reagents were prepared according to manufacturer’s 
instructions. 50 µL of assay buffer was added into all the wells in the ELISArray 
plate. The negative control, positive control and samples were loaded into the 
appropriate wells and incubated for 2 hours. This allows the target antigen to 
bind to the plate. The plate was then washed 3 times. Detection antibodies 
Identification of Pathways Effected in Solamargine Treatment 
Page 62 
 
were added into the respective wells and incubated again for 1 hour. Detection 
antibody binds to the antigens that were bound to the plate. The plate was then 
washed 3 times. Avidin-HRP was added to the wells and incubated for 30 
minutes, allowing for the detection of the detection antibody. The plate was 
washed 4 times and development solution was added. After an incubation of 
15 minutes in the dark, the stop solution was added. The plate was read using 
Tecan infinite 200 Pro Microplate Reader (Switzerland) at a wavelength of 450 
nm with 570 nm as the reference wavelength.  
 The corrected absorbance value was obtained by subtracting the 
observed absorbance by the absorbance of the negative control, which 
contained only sample dilution buffer. Absorbance values that were less than 
twice that of their negative controls were not interpreted. Further normalization 
was performed using total protein concentration. The data was then analysed 
for differences before and after drug treatment using an unpaired T-test.   
 
4.4. Results 
4.4.1. Quality of RNA extracted 
 The samples were named according to: untreated MGH cells (MB), 
treated MGH cells (MT), untreated UMUC-3 cells (UB) and treated UMUC-3 
cells (UT). The number behind each sample type indicates biological replicates.  
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Table 6. The total nucleic acid content, OD260/280 and OD260/230 values for 









MB1 316.95 15847.5 1.97 2.12 
MB2 218.15 10907.5 1.99 2.37 
MB3 315.71 15785.5 2.07 2.23 
MT1 135.01 6750.5 2.16 1.73 
MT2 97.27 4863.5 2.00 1.65 
MT3 155.23 7761.5 1.95 2.37 
UB1 103.22 5161.0 1.88 1.90 
UB2 127.46 6373.0 1.92 1.75 
UB3 128.05 6402.5 1.84 2.00 
UT1 140.41 7020.5 1.86 2.13 
UT2 225.89 11294.5 1.85 2.33 
UT3 176.49 8824.5 1.91 2.33 
 
 From Table 6, the quantity and quality of the RNA extracted met the 
requirements for the microarray.  
 
4.4.2. Microarray Data Quality 
 The quality of the microarray data was assessed before analyzing the 
microarray data obtained.   




Figure 25. Control summary plots of the microarray data obtained.  
 
Table 7. Expected value for each control metric parameter. 
 Internal control Expected value 
1 Hybridization Controls High > Medium > Low 
2 Low Stringency PM > MM2 
3 Biotin and High Stringency Biotin is high 
4 
Negative Controls                  
(Background and Noise) 
Low 
5 
Gene Intensity                          
(House-Keeping and All Genes) 
Higher than Background 
(Housekeeping > All Genes) 
6 Labeling and Background (optional) 
 
Identification of Pathways Effected in Solamargine Treatment 
Page 65 
 
 Controls were included into the hybridization assay to identify any 
problems and ensure that the sample labelling, microarray hybridization, 
washing and staining were performed well [272]. The control summary plots 
(Figure 25), examined six aspects of internal control, which were: hybridization 
controls, low stringency, biotin and high stringency, negative controls, gene 
intensity and labelling and background. All six control metric met the expected 
value as seen in Table 7.    
 
 
Figure 26. A plot of the total number of probes detected across all samples.  
 
 For probes to be counted, the p-value threshold was determined at less 
than 0.05. In this plot (Figure 26), the number of probes detected across all 
samples were similar, which was indicative of samples of high quality. An 
abnormally low probe detection could indicate samples with high background, 
low signal or poor stringency [272].  




Figure 27. A logarithmic box plot of the average signals in the samples (left) and 
quantile normalization of the signal obtained (right).  
 
 Using the logarithm of the signal obtained ensured an even 
representation of the data. The logarithmic box plot (Figure 27) showed a 
typical distribution of the signal intensities. After normalization, the median 
values and distribution across replicates were similar, indicating that the data 
and normalization performed was satisfactory.  
 
 
Figure 28. The density plot of the signal obtained before (left) and after (right) 
quantile normalization.  
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 The density plot (Figure 28) was plotted to ensure that the distribution 
of the probes after normalization was consistent across the chip. After 
normalization, no anomaly was seen and the distribution of the probes was 
consistent. Hence, the data was suitable for further analysis.  
 
 
Figure 29. A scatter plot to see the degree of reproducibility between samples.  
 
 The scatter plot (Figure 29) was plotted to evaluate for problems 
pertaining to poor sample quality, image saturation, large variations in signal 
and inconsistent stringency. In general, replicates would have scatter plots of 
signal intensities demonstrating a symmetrical distribution of data points about 
the 45 ° line, also called identity line. The scatter plot was also observed for 
coherence between best fit line and identity line and any non-linear distributions 
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[273]. From the scatter plot, occasional asymmetry was observed. But in 
general, data points were symmetrical about the identity line. The Pearson’s 
correlation values of more than 0.9 indicate high positive correlation between 
the samples.  
 
 
Figure 30. Correlation matrix of all 12 samples.  
 
 The correlation matrix (Figure 30) was obtained to understand the 
dependence between the 12 samples examined. From the plot, the six UMUC-
3 samples have high correlation to each other and likewise, this was also seen 
in the six MGH samples. The UMUC-3 samples and MGH samples were 
distinct from each other. Between non-treated and treated samples, a 
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segregation could also be seen for MGH samples. However, no obvious 
segregation was visible between non-treated and treated UMUC-3 samples.  
 
 
Figure 31. The samples were grouped according using hierarchical clustering.  
 
 
Figure 32. A multidimensional scaling (MDS) plot of the 12 samples.  
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 With the use of hierarchical clustering (Figure 31), two separate clusters 
were seen, differentiating between MGH and UMUC-3 samples. Within the 
MGH cluster, MB samples were observed to be segregated from the MT 
samples. However, within the UMUC-3 cluster, there was no clear 
differentiation between the UB and UT samples. The multidimensional scaling 
(MDS) plot (Figure 32) also confirmed this finding. Hence, untreated and 
treated UMUC-3 samples will not be compared.  
 All in all, from the various data quality plots, the microarray data was 
deemed satisfactory for further analysis.  
 
4.4.3. Microarray Data Pre-Processing 
 Data was pre-processed through filtering, transformation and 
normalization to reduce systematic bias. First, probe quality was checked by 
counting only probes that had p-value of less than 0.05. Next, transformation 
of the data was performed by taking the logarithm of the probes assuming equal 
variance. Lastly, normalization was done by quantile normalization of the log2 
values of the probes in R.  
 Identified probes were further filtered based on a cut-off of at least two-
fold differential expression. Comparing MGH and UMUC-3 cells, 3539 probes 
representing 3013 genes were found to be differentially regulated. Comparing 
MGH treated and untreated with SOM, 400 probes representing 354 genes 
were found to be differentially regulated.   
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4.4.4. Microarray Profiling of MGH and UMUC-3 Cells 
Table 8. Top 50 genes overexpressed between MGH and UMUC-3 cells 




Summary of Function 
NM_000600.1 IL6 142.69 
Signalling molecule, 
Interleukin 
NM_175617.3 MT1E 117.54 - 
NM_001007538.1 SHISA2 68.95 - 
NM_001553.1 IGFBP7 63.65 
Miscellaneous 
function 
NM_004428.2 EFNA1 61.74 - 
NM_004591.1 CCL20 53.73 
Signalling molecule, 
Chemokine 
NM_021101.3 CLDN1 44.08 Tight junction 
NM_005329.2 HAS3 37.70 Glycosyltransferase 
XR_040455.1 LOC645638 31.52 - 
NM_012413.3 QPCT 29.55 Transferase 
NM_006963.3 ZNF22 25.05 Transcription factor 
NM_000126.2 ETFA 23.75 - 
NM_080757.1 C20orf127 23.26 - 
NM_005195.3 CEBPD 21.73 
Transcription factor, 
Nucleic acid binding 
NM_201629.1 TJP2 18.69 Tight junction 
NM_000758.2 CSF2 18.42 
Signalling molecule, 
Cytokine 
NM_032578.2 MYPN 18.29 - 
NM_014638.2 PLCH2 16.57 Phospholipase 
NM_130445.2 COL18A1 15.94 
Extracellular matrix 
structural protein 
NM_006720.3 ABLIM1 15.65 
Miscellaneous 
function 
NM_003714.2 STC2 15.58 Peptide hormone 
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NM_182758.1 WDR72 14.97 - 
NM_019885.2 CYP26B1 14.03 Oxygenase 
NM_133467.2 CITED4 13.37 Transcription cofactor 
NM_052969.1 RPL39L 13.18 Ribosomal protein 
NM_017456.1 PSCD1 12.79 
Guanyl-nucleotide 
exchange factor 
NM_015253.1 WSCD1 12.68 Transferase 
NM_000228.2 LAMB3 12.64 
Extracellular matrix 
linker protein 
NM_000584.2 IL8 12.46 
Signalling molecule, 
Chemokine 
NM_017456.2 CYTH1 12.31 
Guanyl-nucleotide 
exchange factor 
NM_001005920.2 JMJD8 12.20 Receptor 
NM_001511.1 CXCL1 11.37 
Signalling molecule, 
Chemokine 
NM_002780.3 PSG4 11.20 
CAM family adhesion 
molecule 
NM_022748.10 TNS3 11.10 - 
NM_002993.2 CXCL6 10.82 
Signalling molecule, 
Chemokine 
NM_000071.1 CBS 10.61 Synthase 
NM_014498.2 GOLPH4 10.05 - 
NM_001032394.1 GPR126 10.01 
G-protein coupled 
receptor 
NM_175859.1 CTPS2 9.70 Synthase 
NM_006681.1 NMU 9.26 - 
NM_002451.3 MTAP 9.15 Phosphorylase 
NM_144584.1 C1orf59 8.69 - 
NM_023930.3 KCTD14 8.58 Regulatory molecule 
NM_022337.1 RAB38 8.42 Small GTPase 
NM_001034996.1 RPL14 8.16 Ribosomal protein 
NM_001005474.1 NFKBIZ 7.98 - 
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NM_002089.3 CXCL2 7.91 
Signalling molecule, 
Chemokine 
NM_130435.2 PTPRE 7.68 Phosphatase 
NM_014376.2 CYFIP2 7.62 G-protein modulator 
NM_015881.5 DKK3 7.37 - 
 
Table 9. Top 50 genes underexpressed between MGH and UMUC-3 cells 




Summary of Function 
NM_145040.2 PRKCDBP -42.96 Transcription factor  
NM_000527.2 LDLR -31.13 Receptor 
NM_002247.2 KCNMA1 -26.94 
Voltage-gated 
potassium channel 
NM_005242.3 F2RL1 -25.80 
G-protein coupled 
receptor 
NM_032461.2 SPANXB1 -24.29 - 
NM_001001936.1 AFAP1L2 -23.01 - 
NM_000358.1 TGFBI -22.61 
Cell adhesion 
molecule 
NM_033377.1 CGB1 -20.80 - 
NM_002775.3 HTRA1 -19.81 Serine protease 
NM_001759.2 CCND2 -18.73 Kinase activator 
NM_015444.2 TMEM158 -18.33 - 
NM_181702.1 GEM -17.80 Small GTPase 
NM_003378.2 VGF -17.23 Signalling molecule 
NM_000602.1 SERPINE1 -16.40 
Serine protease 
inhibitor 
XM_001128032.1 MGC87042 -16.12 - 
NM_001958.2 EEF1A2 -15.82 
Translation elongation 
factor 
XM_001132404.1 C14orf78 -14.35 - 
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NM_002333.1 LRP3 -14.01 Receptor 
NM_012449.2 STEAP1 -13.56 - 
NM_000153.2 GALC -13.16 Galactosidase 
NM_024697.1 ZNF385D -13.10 Transcription factor 
NM_001423.1 EMP1 -11.92 Cytoskeletal protein 
NM_178507.2 OAF -11.90 - 
NM_016249.2 MAGEC2 -11.56 - 
NM_005346.3 HSPA1B -11.43 
Hsp 70 family 
chaperone 
NM_153321.1 PMP22 -10.27 Cytoskeletal protein 
NM_006096.2 NDRG1 -10.20 - 
NM_016463.5 CXXC5 -10.08 - 
NM_020645.1 NRIP3 -10.06 Transcription cofactor 
NM_152737.2 RNF182 -10.01 - 
NM_138420.2 AHNAK2 -9.94 - 
NR_024430.1 LOC399959 -9.63 - 
NM_006410.3 HTATIP2 -9.50 - 
NM_175868.1 MAGEA6 -9.43 - 
NM_001018111.1 PODXL -9.18 - 
NM_032843.3 FIBCD1 -9.14 - 
NM_004502.3 HOXB7 -9.13 
Transcription factor, 
Nucleic acid binding 
NM_005434.3 MALL -8.97 
Miscellaneous 
function 
NM_002145.3 HOXB2 -8.82 
Transcription factor, 
Nucleic acid binding 




NM_004093.2 EFNB2 -8.31 
Membrane-bound 
signalling molecule 
NM_024943.1 TMEM156 -8.26 - 
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NM_032883.1 C20orf100 -7.75 - 
NM_006417.3 IFI44 -7.63 - 
NM_000494.3 COL17A1 -7.50 
Extracellular matrix 
structural protein 
NM_021021.2 SNTB1 -7.38 Cytoskeletal protein 
NM_013230.2 CD24 -7.10 - 
NM_021623.1 PLEKHA2 -6.99 - 
NM_001042437.1 ST3GAL5 -6.98 Glycosyltransferase 
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Table 10. Pathways that were enriched after comparing MGH and UMUC-3 cells, as analysed by Partek Genomics Suite 6.6    









in list, in 
pathway 
# genes not 
in list, in 
pathway 
# genes in 
list, not in 
pathway 
# genes not 
in list, not in 
pathway 
TNF signalling pathway kegg_pathway_243 15.94 1.2E-07 23.64 26 84 475 6003 
Amoebiasis kegg_pathway_214 10.93 1.8E-05 20.18 22 87 479 6000 
Legionellosis kegg_pathway_39 10.06 4.3E-05 25.45 14 41 487 6046 
Rheumatoid arthritis kegg_pathway_170 9.21 1.0E-04 20.22 18 71 483 6016 
NF-κB signalling pathway kegg_pathway_163 8.76 1.6E-04 19.57 18 74 483 6013 
PI3K-Akt signalling pathway kegg_pathway_262 8.57 1.9E-04 13.08 45 299 456 5788 
Pathways in cancer kegg_pathway_74 8.28 2.5E-04 13.11 43 285 458 5802 
Nicotinate and nicotinamide 
metabolism 
kegg_pathway_81 7.35 6.4E-04 29.63 8 19 493 6068 
Small cell lung cancer kegg_pathway_84 7.34 6.5E-04 18.60 16 70 485 6017 
Chagas disease (American 
trypanosomiasis) 
kegg_pathway_228 7.20 7.5E-04 17.31 18 86 483 6001 
NOD-like receptor signalling 
pathway 
kegg_pathway_91 6.93 9.8E-04 21.05 12 45 489 6042 
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Glutathione metabolism kegg_pathway_132 6.66 1.3E-03 21.57 11 40 490 6047 
Prion diseases kegg_pathway_105 6.55 1.4E-03 24.32 9 28 492 6059 
Drug metabolism - 
cytochrome P450 
kegg_pathway_26 6.45 1.6E-03 19.12 13 55 488 6032 
Cytokine-cytokine receptor 
interaction 
kegg_pathway_79 6.36 1.7E-03 12.78 34 232 467 5855 
Cell adhesion molecules  kegg_pathway_117 6.17 2.1E-03 14.89 21 120 480 5967 
Malaria kegg_pathway_119 5.89 2.8E-03 20.83 10 38 491 6049 
Transcriptional misregulation 
in cancer 
kegg_pathway_34 5.66 3.5E-03 13.64 24 152 477 5935 
Chemokine signalling 
pathway 
kegg_pathway_255 5.51 4.1E-03 13.30 25 163 476 5924 
ECM-receptor interaction kegg_pathway_242 5.40 4.5E-03 16.47 14 71 487 6016 
Hematopoietic cell lineage kegg_pathway_159 5.19 5.6E-03 16.09 14 73 487 6014 
Bladder cancer kegg_pathway_171 5.00 6.7E-03 21.05 8 30 493 6057 
Chemical carcinogenesis kegg_pathway_266 4.98 6.8E-03 16.25 13 67 488 6020 
Prolactin signalling pathway kegg_pathway_9 4.89 7.5E-03 16.67 12 60 489 6027 
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Toxoplasmosis kegg_pathway_72 4.89 7.5E-03 14.41 17 101 484 5986 
HTLV-I infection kegg_pathway_190 4.87 7.7E-03 11.92 31 229 470 5858 
Type II diabetes mellitus kegg_pathway_2 4.69 9.2E-03 18.75 9 39 492 6048 
Tight junction kegg_pathway_257 4.47 1.1E-02 13.53 18 115 483 5972 
Focal adhesion kegg_pathway_188 4.36 1.3E-02 12.14 25 181 476 5906 
Glycosaminoglycan 
biosynthesis - chondroitin 
sulfate / dermatan sulfate 
kegg_pathway_61 4.21 1.5E-02 25.00 5 15 496 6072 
Toll-like receptor signalling 
pathway 
kegg_pathway_56 4.21 1.5E-02 14.02 15 92 486 5995 
Jak-STAT signalling pathway kegg_pathway_40 4.19 1.5E-02 12.74 20 137 481 5950 
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Table 11. Top 10 pathways that were not enriched after comparing MGH and UMUC-3 cells, as analysed by Partek Genomics Suite 6.6  









in list, in 
pathway 
# genes not 
in list, in 
pathway 
# genes in 
list, not in 
pathway 
# genes not 
in list, not in 
pathway 
Hedgehog signalling pathway kegg_pathway_67 6.25 1.9E-03 13.73 7 44 226 6311 
Melanogenesis kegg_pathway_133 5.85 2.9E-03 9.90 10 91 223 6264 
Wnt signalling pathway kegg_pathway_230 5.62 3.6E-03 8.63 12 127 221 6228 
Mucin type O-Glycan 
biosynthesis 
kegg_pathway_107 5.61 3.7E-03 16.67 5 25 228 6330 
Cell adhesion molecules  kegg_pathway_117 5.51 4.1E-03 8.51 12 129 221 6226 
Glycosaminoglycan 
biosynthesis - chondroitin 
sulfate / dermatan sulfate 
kegg_pathway_61 5.35 4.7E-03 20.00 4 16 229 6339 
Hippo signalling pathway kegg_pathway_96 4.81 8.2E-03 7.79 12 142 221 6213 
Bladder cancer kegg_pathway_171 4.58 1.0E-02 13.16 5 33 228 6322 
Calcium signalling pathway kegg_pathway_237 4.46 1.2E-02 7.18 13 168 220 6187 
Endocytosis kegg_pathway_232 4.42 1.2E-02 6.93 14 188 219 6167 
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The genes that had a fold change of more than 2 after comparing MGH and 
UMUC-3 cells were tabulated in Table 8 and 9. The pathways that were 
enriched in MGH cells compared to UMUC-3 cells were presented in Table 10. 
Table 11 showed the pathways that were not enriched in MGH cells compared 
to UMUC-3 cells. Pathway maps for TNF signalling pathway, NF-κB signalling 
pathway, PI3K-Akt signalling pathway, pathways in cancer and nucleotide 
oligomerization domain (NOD)-like receptor signalling pathway showing the 
gene up or down-regulation, where up-regulated genes were indicated in red 
and down-regulated genes were indicated in green, can be found in Figure 48 
– 52 in the Appendices.  
 The Figures 33 – 38 below were the analyses of the microarray results 
generated by DAVID.  
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Figure 33. Top 10 biological process gene ontology category differences between 
MGH and UMUC-3 cells.  
 
Figure 34. Top 10 cellular component gene ontology category differences between 
MGH and UMUC-3 cells. 
 




Figure 35. Top 10 molecular function gene ontology category differences between 
MGH and UMUC-3 cells. 
 




Figure 36. Top 10 INTERPRO protein domain differences between MGH and 
UMUC-3 cells. 




Figure 37. Top 10 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway 
differences between MGH and UMUC-3 cells. 
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4.4.5. Microarray Profiling of Treated and Untreated MGH Cells 
Table 12. Differentially regulated genes in MGH cells after 3 hours of SOM 
treatment 




Summary of Function 
NM_005252.2 FOS 27.98 
Transcription factor, 
Nucleic acid binding 
XM_001713808.1 LOC100132564 20.01 - 
NM_006732.1 FOSB 10.75 
Transcription factor, 
Nucleic acid binding 
NM_001040619.1 ATF3 7.63 
Transcription factor, 
Nucleic acid binding 
NM_004419.3 DUSP5 4.23 Protein phosphatase 
NM_014330.2 PPP1R15A 4.16 
Miscellaneous 
function 
NM_003407.2 ZFP36 4.13 Nucleic acid binding 
NM_006186.2 NR4A2 4.06 
Nuclear hormone 
receptor 




NM_001964.2 EGR1 3.79 
Transcription factor, 
Nucleic acid binding 
XM_941665.2 LOC387763 3.51 - 
NM_033027.2 AXUD1 3.41 - 
NM_002133.1 HMOX1 3.40 Oxidoreductase 
XM_001127070.1 LOC728285 3.20 Cytoskeletal protein 
NM_018948.2 ERRFI1 3.12 - 
NM_001901.1 CTGF 2.91 Signalling Molecule 
NM_000602.1 SERPINE1 2.86 
Serine protease 
inhibitor 
NM_015444.2 TMEM158 2.61 - 
NM_004591.1 CCL20 2.61 
Signalling Molecule, 
Chemokine 
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NM_002089.3 CXCL2 2.55 
Signalling Molecule, 
Chemokine 
NM_025195.2 TRIB1 2.52 Protein kinase 
NM_001039667.1 ANGPTL4 2.48 Extracellular matrix 
NM_016270.2 KLF2 2.46 Transcription Factor 
NM_002309.2 LIF 2.46 
Signalling molecule, 
Cytokine 
NM_173670.2 RGMB 2.43 - 
NM_002923.1 RGS2 2.42 G-protein modulator 
NM_080730.2 IFFO1 2.41 - 
NM_013386.3 SLC25A24 2.40 
Mitochondrial carrier 
protein 
NM_001945.1 HBEGF 2.40 
Signalling molecule, 
Growth factor 
NM_004417.2 DUSP1 2.38 Protein phosphatase 
NR_003287.1 LOC100008589 2.38 - 
NM_000779.2 CYP4B1 2.37 Oxidoreductase 
NM_001300.4 KLF6 2.36 Transcription factor 
NM_000389.2 CDKN1A 2.35 Kinase inhibitor 
NM_003897.3 IER3 2.34 - 
NM_002756.3 MAP2K3 2.32 
Protein kinase, 
Transferase 
NM_004907.2 IER2 2.31 - 
XM_939919.2 LOC650832 2.30 
Protein kinase, 
Transferase 
NM_001423.1 EMP1 2.30 Cytoskeletal protein 
NM_003155.2 STC1 2.28 Signalling molecule 
NR_029858.1 MIR302C 2.27 - 
NM_007350.3 PHLDA1 2.24 - 
NM_173354.3 SIK1 2.22 - 
NM_012323.2 MAFF 2.22 
Transcription factor, 
Nucleic acid binding 
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NM_015714.2 G0S2 2.21 - 
NM_004083.4 DDIT3 2.21 - 
XM_001715065.1 LOC100129543 2.19 - 
NM_019058.2 DDIT4 2.19 - 
NM_013376.3 SERTAD1 2.17 Transcription factor 
NM_001924.2 GADD45A 2.14 
Miscellaneous 
function 
XM_926402.1 LOC643031 2.11 Oxidoreductase 
NM_001554.3 CYR61 2.10 
Signalling molecule, 
Growth factor 
NM_002970.1 SAT1 2.10 Acetyltransferase 
NM_000600.1 IL6 2.10 
Signalling molecule, 
Interleukin 
NM_004235.3 KLF4 2.10 Transcription factor 
NM_021960.3 MCL1 2.06 Signalling molecule 
NM_178181.1 CDCP1 2.05 - 
NM_002228.3 JUN 2.05 
Transcription factor, 
Nucleic acid binding 
NM_032558.2 HIATL1 2.02 Transporter 
NM_032336.1 GINS4 -2.01 - 
NM_003574.5 VAPA -2.01 
Membrane traffic 
regulatory protein 




NM_182922.2 HEATR3 -2.03 - 
NM_005733.1 KIF20A -2.06 
Microtubule binding 
motor protein 
NM_001032291.1 PSRC1 -2.15 - 
NM_030919.2 FAM83D -2.26 - 
NM_181353.1 ID1 -2.29 Transcription factor 
NM_017939.1 FLJ20718 -2.31 - 
Identification of Pathways Effected in Solamargine Treatment 
Page 89 
Table 13. Pathways that were enriched after comparing SOM-treated and untreated MGH cells 









in list, in 
pathway 
# genes not 
in list, in 
pathway 
# genes in 
list, not in 
pathway 
# genes not 
in list, not in 
pathway 
TNF signalling pathway kegg_pathway_243 25.63 7.4E-12 9.09 10 100 17 6461 
MAPK signalling pathway kegg_pathway_261 12.12 5.4E-06 3.13 8 248 19 6313 
Salmonella infection kegg_pathway_71 10.74 2.2E-05 5.81 5 81 22 6480 
Rheumatoid arthritis kegg_pathway_170 10.57 2.6E-05 5.62 5 84 22 6477 
Chagas disease (American 
trypanosomiasis) 
kegg_pathway_228 9.82 5.5E-05 4.81 5 99 22 6462 
Toll-like receptor signalling 
pathway 
kegg_pathway_56 9.68 6.2E-05 4.67 5 102 22 6459 
NOD-like receptor signalling 
pathway 
kegg_pathway_91 9.48 7.6E-05 7.02 4 53 23 6508 
FoxO signalling pathway kegg_pathway_86 8.68 1.7E-04 3.79 5 127 22 6434 
Leishmaniasis kegg_pathway_4 8.57 1.9E-04 5.56 4 68 23 6493 
Pertussis kegg_pathway_273 8.36 2.3E-04 5.26 4 72 23 6489 
NF-κB signalling pathway kegg_pathway_163 7.62 4.9E-04 4.35 4 88 23 6473 
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HIF-1 signalling pathway kegg_pathway_113 7.09 8.4E-04 3.77 4 102 23 6459 
Legionellosis kegg_pathway_39 6.57 1.4E-03 5.45 3 52 24 6509 
Osteoclast differentiation kegg_pathway_17 6.30 1.8E-03 3.05 4 127 23 6434 
Inflammatory bowel disease  kegg_pathway_22 6.05 2.4E-03 4.55 3 63 24 6498 
p53 signalling pathway kegg_pathway_32 5.96 2.6E-03 4.41 3 65 24 6496 
Amphetamine addiction kegg_pathway_114 5.96 2.6E-03 4.41 3 65 24 6496 
Non-alcoholic fatty liver 
disease  
kegg_pathway_120 5.90 2.7E-03 2.74 4 142 23 6419 
Hepatitis B kegg_pathway_89 5.88 2.8E-03 2.72 4 143 23 6418 
Cytokine-cytokine receptor 
interaction 
kegg_pathway_79 5.52 4.0E-03 1.88 5 261 22 6300 
Influenza A kegg_pathway_104 5.29 5.0E-03 2.31 4 169 23 6392 
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Table 14. Pathways that were not enriched after comparing SOM-treated and untreated MGH cells 









in list, in 
pathway 
# genes not 
in list, in 
pathway 
# genes in 
list, not in 
pathway 
# genes not 
in list, not in 
pathway 
Oocyte meiosis kegg_pathway_29 3.40 0.03 0.90 1 110 1 6476 
Tight junction kegg_pathway_257 3.22 0.04 0.75 1 132 1 6454 
 
 The genes that had a fold change of more than 2 after SOM treatment were tabulated in Table 12. The pathways that were enriched after 
the SOM treatment were presented in Table 13. Table 14 showed the pathways that were not enriched after SOM treatment. Pathway maps for 
TNF signalling pathway, MAPK signalling pathway and Toll-like receptor signalling pathway showing the gene up or down-regulation, where up-
regulated genes were indicated in red and down-regulated genes were indicated in green, can be found in Figures 53 – 55 in the Appendices.   
  The Figures 39 – 44 below were the analyses of the microarray results generated by DAVID.  
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Figure 39. Top 10 biological process gene ontology category differences between 
MGH cells untreated and treated with SOM. 
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Figure 40. Top 10 cellular component gene ontology category differences between 
MGH cells untreated and treated with SOM. 
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Figure 41. Top 10 molecular function gene ontology category differences between 
MGH cells untreated and treated with SOM. 
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Figure 42. Top 10 INTERPRO protein domain differences between MGH cells 
untreated and treated with SOM. 
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Figure 43. Top 10 KEGG pathway differences between MGH cells untreated and 
treated with SOM. 
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Figure 44. Top 10 BioCarta pathway differences between MGH cells untreated 
and treated with SOM. 
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4.4.6. Solamargine Increased Phosphorylation of p38, ERK1/2 and JNK 
 
Figure 45. Western blot of proteins p-p38, p38, p-ERK1/2, ERK1/2, p- SAPK/JNK, 
JNK2 and β-actin. Cell lysate was harvested for MGH and UMUC-3 cell line at time 
points of 0, 2, 6 and 24 hours after treatment with SOM at IC50 concentration. 
Duplicates were performed.  
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Figure 46. Fold change of ratio of p-protein and t-protein relative to β-actin levels, 
as quantified by ImageJ.    
 
 SOM increased the phosphorylation of p38, ERK1/2 and JNK in MGH 
cells in a time-dependent manner. The phosphorylation of ERK and JNK 
proteins were shown to peak at 6 hours post-treatment while phosphorylation 
of p38 increased up to 24 hours post-treatment (Figure 46). In UMUC-3 cells, 
phosphorylation of JNK also peaked at 6 hours post-treatment (Figure 46).   
 Even though it was observed that there was an increase in absolute 
phosphorylation of p38 and ERK1/2 in UMUC-3 cells up to 6 hours post-
treatment (Figure 45), the increase in expression of total p38 and total ERK1/2 
resulted in a subsequent decrease in the ratio of phosphoprotein (p-protein) 
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4.4.7. IL-6, IL-8 and GM-CSF were Constitutively Produced in MGH Cells 
and SOM reduced IL-8 production in both Cell Lines 
 
Figure 47. Bar graph of cytokines produced by the two cell lines analysed using 
Human Inflammatory Cytokines Multi-Analyte ELISArray Kit. Asterisks (*) indicate 
significant differences with p-value < 0.05.  
 
 Out of all the cytokines analysed, only levels of cytokines IL-6, IL-8 and 
GM-CSF for MGH cell line and IL-8 for UMUC-3 cell line were interpreted based 
on the analysis criteria. The treatment of the cell lines with SOM did not result 
in a significant change in the production of cytokines. At a p-value of less than 
0.05, only the production of IL-8 in UMUC-3 and MGH cells decreased after 
treatment. Comparing the two cell lines, cytokines IL-6, IL-8 and GM-CSF were 
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4.5. Discussion 
4.5.1. Microarray Uncovers Pathway Alterations 
 Many genes were up and down-regulated when comparing MGH and 
UMUC-3 cells. Through the pathway analysis, patterns of different gene 
expression were better observed. Several pathways were both enriched in 
MGH cells after SOM treatment and in MGH cells as compared to UMUC-3 
cells. These pathways were tumour necrosis factor (TNF) signalling pathway, 
nuclear factor-kappa B (NF-κB) signalling pathway, NOD-like receptor 
signalling pathway, toll-like receptor signalling pathway and cytokine-cytokine 
interaction. Pathways that are involved in various diseases were also found to 
be enriched in these two groups, such as legionellosis, rheumatoid arthritis and 
Chagas disease. On the other hand, there were no pathways that was both 
enriched in UMUC-3 cells and in MGH cells after SOM treatment.  
 It was interesting to observe that SOM further enriched pathways that 
were already enriched in MGH as compared to UMUC-3 cells. It is unclear 
though, how the further enrichment of these pathways could contribute to 
differential sensitivity of the two bladder cancer cell lines to the drug. Further 
cellular work with the use of inhibitors would be necessary to elucidate the 
molecular basis for this difference.  
 
4.5.2. Signalling Pathways Enhancements after Solamargine Treatment  
 For both comparisons, TNF signalling was found to be the most 
enriched pathway. It was earlier demonstrated that SOM was able to increase 
the expression of TNF receptors (TNF-R) 1 and 2 in lung cancer [125] and liver 
hepatoma cells [126] and TNF-R1 and TNF-R2 are involved in SOM-mediated 
apoptosis.  
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 TNF signalling pathway is involved in many processes, both tumour 
promoting and anti-tumour, such as necrotic and apoptotic cell death, cell 
proliferation, differentiation, invasion and metastasis [274-276]. The TNF 
signalling pathway exert its effect largely through p38 MAPK, JNK and NF-κB 
pathways [275]. The cellular outcome in the activation of TNF signalling 
pathway is dependent on the crosstalk between the NF-κB and JNK [274, 277].  
 Here, it is proposed that the TNF signalling pathway activation led to 
the activation of p38 MAPK, JNK and NF-κB pathways which were all seen in 
the analysis of the enriched pathways in the microarray. Given that TNF 
signalling has a role in inflammation [274], this explained why pathways that 
are involved in inflammatory diseases such as legionellosis, rheumatoid 
arthritis and chagas disease were found enriched as well. It is hypothesised 
that in MGH cells, the activation of TNF signalling pathway plays a role in 
tumour promotion, growth, invasion and metastasis while SOM treatment lead 
to an activation of TNF signalling pathway by increasing JNK activation greatly, 
thereby affecting the cellular outcome.   
 The activation of NF-κB signalling pathway can be both pro- and anti-
tumorigenesis. In its role to promote tumor progression, the activation of NF-
κB signalling pathway can be anti-apoptotic and can lead to metastasis [278], 
angiogenesis [279], proliferation, immortalization and inflammation [280]. On 
the other hand, it can also be anti-tumorigenesis, reducing proliferation, 
suppressing transformation and bring about p53 mediated apoptosis [280]. 
However, in the context of cancer cells, upregulation of NF-κB signalling could 
lead to drug resistance through anti-apoptotic mechanisms [281, 282]. Other 
studies have cited anti-cancer effects of NF-κB inhibitors [283, 284]. Yang, et 
al. reported that the anti-cancer efficacy of huachansu, which also activated the 
NF-κB signalling pathway in bladder cancer cells, was potentiated with the co-
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administration of a NF-κB inhibitor [285]. Sustained JNK signalling, observed 
in Section 4.4.6 and further explained in Section 4.5.3, is pro-apoptotic and can 
be suppressed by NF-κB activation [286-288].  
 Altogether, these suggested that the activation of NF-κB signalling 
pathway by SOM could be detrimental to its cytotoxicity in cancer cells and the 
co-treatment of SOM with a NF-κB inhibitor could increase its efficacy.  
 
4.5.3. Mitogen-Activated Protein Kinase Signalling in Bladder Cancer 
Cells 
 Within the family of MAPK, there are four major pathways: ERK1/2, Big 
MAP kinase (BMK), JNK and p38 MAPK [289]. Of these, ERK1/2, JNK and p38 
MAPK pathways were investigated through western blots. Each of these 
pathways comprise of three tiers in the protein activation cascade where MAPK 
is activated by phosphorylated mitogen-activated protein kinase kinase 
(MAPKK) and MAPKK is activated upon activation of mitogen-activated protein 
kinase kinase kinase (MAPKKK) [290, 291]. While ERK1/2 is activated by 
growth factors and is crucial for cell proliferation [292], JNK and p38 MAPK 
pathways are activated by stresses arising from the cellular environment, pro-
inflammatory cytokines or genotoxic agents and influence cell proliferation, 
differentiation, survival and migration [289, 293]. In general, ERK1/2 functions 
as a survival factor while JNK and p38 MAPK function to promote apoptosis 
[294].  
 This study is the first study to discover the time-dependent p38 MAPK, 
JNK and ERK1/2 activation in bladder cancer cells in response to SOM 
treatment. Published literature has shown that p38 MAPK activation often has 
varying outcomes, leading to apoptosis and growth inhibition [295] in some 
cases, and in malignant cells, its activation can also promote growth, 
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differentiation and survival [289, 296]. In bladder cancer, the activation of p38 
MAPK seems to promote carcinogenesis by affecting genes responsible for 
growth factor expression, inflammation and invasion [289].  
 The duration of activation of these MAPKs also has a role in influencing 
the overall outcome. Transient ERK activation promotes growth while 
persistent activation can lead to differentiation or growth arrest [297]. For JNK 
and p38 MAPK, transient activation was shown to promote survival while 
persistent activation promotes apoptosis via TNF-α [298, 299]. Differing 
outcomes of p38 MAPK and JNK activation are possible, likely due to cell type-
specific differences and are stimulus dependent [293, 300].   
 During the log phase growth of bladder cancer, activation of p38 MAPK 
and ERK1/2 have been observed and inhibition of these pathways can reduce 
proliferation [301]. To fully ascertain the consequence of the up or down 
regulation of the various major MAPK pathways in MGH and UMUC-3 cells, 
functional assays evaluating migration, proliferation signalling, angiogenesis, 
etc., should be performed. Inhibitors should also be used to identify 
predominant pathway contributing to apoptosis after SOM treatment.    
 
4.5.4. Inflammatory Response to Solamargine 
 Chronic and persistent inflammation is correlated with an increased risk 
of cancer [302, 303], with almost 25% of all cancers attributed to infections and 
inflammation [304]. Chronic inflammation contributes to tumorigenesis through 
a number of ways. DNA damage can be caused by the generation of reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) by the activated 
immune cells [302, 305]. Persistent inflammation can also provide cells with 
proliferative and neoangiogenesis signals [306, 307]. Overall, a 
microenvironment with chronic inflammation can be predisposed to neoplasia 
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[302]. Inflammation is not only involved in the initiation of cancer, but also its 
progression and subsequently, metastasis [307] and oncogenic changes in 
cells can further exacerbate inflammation through the recruitment of more 
immune cells [303].    
 Intravesical instillation of BCG has been traditionally used as a bladder 
cancer therapy to induce acute inflammation and activate the immune system. 
BCG instillation demonstrated an increase in IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, 
IL-12, TNF-α, IFN-γ and macrophage colony-stimulating factor (M-CSF) in the 
urine of patients [308, 309], whereas in cell lines, BCG treatment resulted in 
the increase in IL-6 and TNF-α secretion by several fold [29]. For any 
intravesical agent to bring about a successful immune response, a strong Th1 
immune response is necessary [51]. As such, high urinary levels of IL-2, a 
cytokine secreted by the CD4+ T lymphocyte, is found to predict for treatment 
efficacy and tumour recurrence [52, 310-312]. Therefore, it would be ideal for 
intravesical agents to elicit immune response leading to an increase in IL-2 
levels. SOM treatment however, was unable to enhance the production of 
cytokines in both cell lines. This is contrary to the findings made by Li, et al. 
that SOM can increase the CD4+/CD8+ ratio thereby stimulating the immune 
response [127]. The difference might be due to the in vivo experimental set up 
and different cancer type.  
 
4.5.5. Inflammatory Molecules Secretion in Bladder Cancer 
 Comparing MGH and UMUC-3 cell lines, IL-6, IL-8 and GM-CSF were 
found to be constitutively secreted in the MGH cell line. This observation was 
confirmed in the microarray results. IL-6 is crucial in the regulation of the growth 
of the tumour as well as its metastatic spread [313]. The expression of IL-6 is 
therefore correlated with poor patient prognosis [314-317] since it promotes 
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growth and metastasis through the activation of janus kinase/signal 
transducers and activators of transcription (JAK/STAT3) signalling [313]. Chen, 
et al. noted that positive staining for IL-6 is largely associated with MIBC rather 
than NMIBC [314] and in vivo, IL-6 production is correlated with the bladder 
cancer stage [318]. IL-8 is another cytokine that is constitutively secreted by 
MGH cell line. Together with IL-6, IL-8 is also associated with poor prognosis 
[319]. Expression of IL-8 is responsible for proliferation, metastasis as well as 
angiogenesis of tumours [320, 321]. The expression of inflammatory cytokines, 
IL-1, IL-6 and IL-8 have been thought to be responsible for cancer stem cell 
renewal [322-325]. Despite evidences supporting the cancer-supporting role of 
cytokines, there have also been literature supporting the cancer-regressing 
effects of cytokine production. Most notably, in the treatment of bladder cancer, 
the use of BCG instillation which is currently the most efficacious therapy in 
reducing recurrence, led to the secretion of IL-1, IL6 and IL-8 [326]. 
 Another cytokine that is also constitutively secreted, GM-CSF, functions 
to stimulate stem cells to produce granulocytes and monocytes, thereby 
resulting in an effective, long-lasting and precise anti-tumour immune response 
[327]. This has led to its applications as a tumour vaccine [328-331]. However, 
in bladder cancer, secretion of GM-CSF or granulocyte-colony stimulating 
factor  (G-CSF) is found to lead to autocrine tumour growth, immune 
suppression and angiogenesis and subsequently, rapidly advancing disease 
[332]. A number of other bladder carcinoma cell lines, HTB9 [333] and 5637 
[334], are also demonstrated to secrete GM-CSF.  
 All in all, the constitutive secretion of IL-6, IL-8 and GM-CSF in MGH 
cells could suggest that MGH cells are more inclined to increased growth, 
metastasis and angiogenesis than UMUC-3 cells. However, with differing 
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outcomes arising from cytokine secretion, additional experiments are 
necessary to evaluate the precise impact of cytokine secretion.  
 One limitation of this study is that the microarray results are not 
sufficiently validated. Further validation of the microarray results through 
experimental techniques such as quantitative polymerase chain reaction 
(qPCR) should be performed to confirm the gene expression changes 
observed.    
 
4.6. Conclusion 
 In conclusion, microarray was performed in two bladder cancer cell lines 
treated with SOM. It was noted that SOM further enriched pathways that were 
already enriched in MGH cells as compared to UMUC-3 cells, though it was 
unclear how this could contribute to differential sensitivity of the two bladder 
cancer cell lines to the drug. Numerous pathways were found to be upregulated 
following SOM treatment but further molecular work would need to be 
performed to validate and understand how the upregulation of these pathways 
led to cell death in bladder cancer cells. From the results, it was hypothesised 
that the treatment of SOM together with a NF-κB inhibitor could increase its 
efficacy. Constitutive production of IL-6, IL-8 and GM-CSF in MGH cells could 
imply an increased growth, metastasis and angiogenesis in MGH cells than 
UMUC-3 cells. Further functional assays assessing for cell migration, 
angiogenesis, et cetera, would be necessary to ascertain the outcomes of 
these pathway activations.  
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CHAPTER 5: DISCUSSION AND FUTURE WORK 
5.1. Solamargine as a Therapeutic Agent 
 In Chapter 2, through cell cytotoxicity assays, SOM was found to 
perform best considering potency and selectivity. Furthermore, SOM was found 
to be rapidly acting, reaching its maximum cell kill within 4 hours of treatment 
[125]. However, a potential drawback would be its narrow therapeutic range, 
with dose-dependent cytotoxicity beginning at 2 µM and causing the death of 
the entire UMUC-3 bladder cancer cell population at 7 µM. For the rest of the 
bladder cell lines, the therapeutic range for SOM was between 5 to 25 µM. 
Notably, even though MET was effective only in high mM concentrations, it was 
found to be selectively potent towards bladder cancer cells.   
 In Chapter 3, the drug combinations of MMC and MET, MMC and SOM, 
SOM and MET were evaluated against bladder cancer to identify synergistic 
combinations that had selective efficacy against bladder cancer cells. All 
combinations were antagonistic for bladder epithelial cells, HUC-1, while some 
degree of synergism was found in some drug combinations against bladder 
cancer cells. Significantly, synergism was observed for SOM and MET drug 
combination against UMUC-3 cells whereas limited synergism was found for 
MMC and SOM drug combination against bladder cancer cells. Lastly the MMC 
and MET drug combination was found to be antagonistic against bladder 
cancer cells. Physicians could be cautious in co-administering drugs for 
bladder cancer patients with type 2 diabetes.  MET, administered for the 
treatment of type 2 diabetes is principally excreted unchanged by renal 
excretion. Hence, intravesical MMC therapy in combination with MET could 
negatively affect the efficacy of MMC while intravesical SOM therapy in 
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combination with MET could augment the efficacy of SOM against bladder 
cancer cells.  
 In Chapter 4, microarray was performed to identify pathways that were 
affected by SOM treatment. SOM was found to further enriched pathways such 
as TNF signalling pathway and NF-κB signalling pathway that were already 
enriched in MGH cells as compared to UMUC-3 cells. However, it was not 
understood how this could contribute to differential sensitivity of the two bladder 
cancer cell lines to the drug. The enrichment of TNF signalling pathway, NF-κB 
signalling pathway and MAPK signalling pathway were discussed and it is 
proposed that the sustained activation of JNK pathway led to apoptosis. The 
concurrent activation of NF-κB signalling pathway could reduce the pro-
apoptotic effect of JNK activation, leading to suggestion that the treatment of 
SOM together with a NF-κB inhibitor could increase its efficacy. Constitutive 
production of IL-6, IL-8 and GM-CSF in MGH cells could imply that MGH cells 
are more prone to increased growth, metastasis and angiogenesis than UMUC-
3 cells. However, in view of differing literature opinions, additional experiments 
are necessary to evaluate the precise impact of cytokine secretion. 
 
5.2. Understanding and Improving Solamargine 
5.2.1. Elucidation of Molecular Targets and Mechanisms 
 Even though SOM was found to act on the MAPK pathway, the exact 
mechanisms leading to this up or down-regulation are still unknown. The 
molecular target of SOM should be elucidated so as to provide a clearer 
understanding behind the differential sensitivity of the drug in various cell lines. 
Mayank and Jaitak have previously noted that SOM is able to bind well to 
molecular targets, such as sonic hedgehog and gli proteins [335]. SOM is likely 
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to be multi-targeting and hence, its other molecular targets should be 
elucidated as well to provide a complete picture. 
 In addition, even though there has been up or down-regulation found in 
the final effectors of the MAPK pathway, signalling pathways function as a 
network and their dependency on time and signalling magnitude necessitates 
that they should be evaluated collectively. Other studies have observed the 
inactivation of PI3K/Akt pathway [336] and inhibition of STAT3 [119] but these 
were not observed in this study (Data not shown). Understanding the influence 
of SOM treatment on the entire cellular signalling system would enable 
improved prediction of treatment outcomes and identification of off-target 
effects, given that cancer cells are heterogeneous, harboring a variety of 
genetic and pathway aberrations. This is even more important in view of 
combinatorial treatments [337].  
 Even though the microarray gene analysis had been helpful in 
elucidating pathways that were enriched following SOM treatment and 
comparing pathway enrichments in MGH and UMUC-3 cells, further molecular 
work involving pathway inhibitors would need to be performed to determine the 
molecular basis for differential sensitivity. This understanding would allow 
treatment to be personalised for patients, achieving better treatment efficacy.  
 
5.2.2. Understanding of How Solamargine leads to Cell Death  
 Through the microarray, we understood that a total of nine signalling 
pathways were affected by SOM treatment in MGH cells. However, without the 
use of specific molecular inhibitors, it is difficult to discern which pathways were 
responsible for the SOM-induced apoptosis. Hence, further cell cytotoxicity 
assays in bladder cancer cells treated with SOM and inhibitor are necessary.  
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 The use of NF-κB inhibitors in combination with SOM should be 
evaluated for possible increase in cytotoxicity.  
 
5.2.3. Functional Assays to Investigate Anti-Tumour Effect 
 Functional assays evaluating the cell migration, invasion, chemotaxis, 
adhesion, angiogenesis, growth factor signalling can be performed to 
understand the anti-tumour effect of SOM. A recent study indicated that 
solamargine can inhibit migration and invasion of human hepatocellular 
carcinoma cells through down-regulation of matrix metalloproteinases 2 and 9 
expression and activity [129]. It would be interesting to confirm whether SOM 
has similar effects on bladder carcinoma cells. 
 
5.2.4. Validation of Microarray Results with Quantitative Polymerase 
Chain Reaction in MGH and UMUC-3 Cells 
 DNA microarrays allow us to screen a large number of genes to 
quantitate for gene expression. However, the quality of the microarray data can 
be highly dependent on the processing steps [338] and can vary depending on 
the platform [339]. The variation present in DNA microarrays coupled with 
limited fluorescence dynamic range mean that they lack specificity and 
sensitivity and are semi-quantitative [340]. Hence, qPCR needs to be 
performed to validate the changes in gene expression observed in the 
microarray results and allow microarray results to be comparable between 
laboratories.     
 
5.2.5. Improving Potency and Selectivity 
 Quantitative structure–activity relationship models (QSAR) can be 
performed on SOM to identify crucial structures that are responsible for the 
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cytotoxic activity of the compound and thereby increasing its potency. QSAR 
can also improve the selectivity of SOM, allowing it to target cancer cells 
specifically.  
 
5.2.6. RT4 Cell Line as an In Vitro Model for NMIBC 
 The efficacy of SOM can be evaluated in RT4 cell line, which is a low-
grade cell line to provide an understanding of the efficacy of SOM if used in 
NMIBC.  
 
5.2.7. In Vitro Efficacy in Human Bladder Primary Cell Lines 
 Given the heterogeneous nature of cancer cells [341] and the increase 
in mutation burden and clonal diversity as tumour grade increases [342], 
primary cell lines are able to mimic in vivo conditions best without using in vivo 
models. Cell lines that have been transformed may undergo changes in cellular 
functions, leading to altered growth characteristics and signalling pathways 
[343]. Even though genetic aberrations may be retained in cell lines, changes 
in gene expression may occur, making them different from the tumours they 
were supposed to model [344]. Hence, using human primary bladder cancer 
cell lines will give us a better reflection of the efficacy of the drug.  
 
5.2.8. In Vivo Efficacy and Pharmacokinetics 
 From the cell cytotoxicity studies, SOM has demonstrated fast-acting 
and potent cell cytotoxic properties. However, the steep dose-response curve 
observed in the various cell lines may indicate a narrow therapeutic range. 
Hence, SOM must be evaluated in a bladder cancer rat model to determine its 
suitability as a bladder cancer intravesical therapeutic. As a potential 
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intravesical agent, the pharmacokinetic properties of SOM in vivo, such as 
cellular uptake and clearance will need to be evaluated.  
 The pharmacokinetics of SOM have been briefly studied by Zheng and 
coworkers [345]. It was found that following intravenous administration, the 
compound can be cleared rapidly from the plasma with a half-life of 3 hours 
and is dose-independent. It will be important to determine its microsomal 
stability and excretion pathway. It will be beneficial if the compound is excreted 
unchanged in the urine.   
 
5.3. Improving Current Therapeutics 
 Aside from investigating SOM as a new bladder cancer therapeutic, 
further work can also involve improving the drug delivery of current therapeutics, 
namely MMC in intravesical chemotherapy.  
 
5.3.1. Thermosensitive Hydrogel Mitomycin C Formulation 
 In Chapter 2, it was shown that the efficacy of MMC treatment benefits 
from an increase in drug exposure time. Given that MMC solution is diluted 
within 5 minutes after instillation due to urine production [91] and patients are 
required to hold their bladder for an hour for the drug to take effect [95], a 
hydrogel formulation of MMC would overcome these inconveniences and 
improve drug efficacy by allowing for a sustained drug release over extended 
periods of time.  
 Earlier studies aiming to improve intravesical drug administration have 
explored the use of thermosensitive hydrogels as a model for sustained drug 
release in vivo and taking advantage of its viscous property at body 
temperature to adhere to the bladder wall. Misoprostol is entrapped in a 
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modified polyethylene glycol (PEG)-poly(lactic-co-glycolic acid) (PLGA)-PEG 
polymer as a feasible hydrogel matrix [346] while a magnetic chitosan hydrogel 
has been developed for BCG delivery [347]. VEGF-loaded PLGA nanoparticles 
(NPs)-embedded thermo-sensitive hydrogel have been effective in maintaining 
sustained delivery as well [348]. All these studies have highlighted the potential 
of thermosensitive hydrogels as a drug delivery system in the bladder. 
 The thermosensitive hydrogel can be formulated with the use of 
chitosan as the mucoadhesive properties of cationic biopolymer will enhance 
adherence to the bladder urothelium which is anionic and hydrophilic [349] 
[347]. Besides, chitosan has also demonstrated to be able to loosen gap 
junctions and enhance the epithelial permeability to drugs at mucosal surfaces 
[347]. Moreover, it has an antitumor role, improving the body’s immune function 
[350].  
 In in vivo experiments, chitosan induces urothelial cell desquamation, 
which is triggered by necrosis. This cytotoxic effect was found only in cells that 
were in direct contact with an appropriately high concentration of chitosan [351]. 
Given that tumor recurrence following resection is often caused by floating cells 
that were released by the surgical operation, agents that prevent cell 
adherence are likely to reduce the extent of recurrence [352]. Following the 
removal of chitosan, it took 60 minutes for the restoration of the urothelium in 
the event of chitosan-induced desquamation. The quick regeneration of the 
superficial layer of urothelial cells minimises the infiltration of urine through the 
urothelium [351]. This also proves that chitosan can be used intravesically 
without any negative long term effects. Hence, chitosan can be used in the 
creation of the thermosensitive hydrogel.  
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5.3.2. Mitomycin C Nanoparticle Formulation 
 MMC can be encapsulated in NPs to increase the stability of the drug, 
avoiding exposure to an acidic environment as MMC is most stable at pH 8 
[353]. In addition, encapsulation can seek to improve the uptake of MMC into 
the bladder urothelium which is limited by its hydrophilic physical property [96].  
Also, given that MMC has insignificant binding to tissues [98], encapsulation 
can improve the drug’s binding to tissues and cellular uptake, and allow MMC 
to target cancer cells specifically, improving efficacy. The nano-sized particles 
would also be able to penetrate deeper into the tissues of the bladder [354], 
allowing complete eradication of bladder cancer cells. This is especially 
important in MIBC.    
 It has been shown that positively charged NPs have a higher level of 
internalization into cells as compared to neutral or negatively charged NPs 
[355]. This is because the cell membrane is negatively charged. Comparatively, 
even though negatively-charged NPs can be taken into the cell, neutrally 
charged NPs avoid interaction with the cell membrane and show minimal 
internalization [355]. Besides a higher cell uptake of positively-charged NPs, 
they also have much stronger endo-lysosomal escape ability [356]. Hence, 
MMC can be encapsulated in a cationic NP.  
 The NPs can be further enhanced by combining it with the 
thermosensitive hydrogel formulation. The hydrogel can improve retention, 
enable the sustained release of the NPs and chitosan in the hydrogel 
formulation loosens the gap junctions in the bladder urothelium, facilitating the 
penetration of the MMC NPs. These NPs can then penetrate deeper into the 
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Pathway Maps Comparing MGH and UMUC-3 cells 
 
Figure 48. TNF Signalling Pathway, colour-coded according to fold change, where 
red means the gene was upregulated and green means the gene was 






Figure 49. NF-κB Signalling Pathway, colour-coded according to fold change, 
where red means the gene was upregulated and green means the gene was 
downregulated.   
 
 
Figure 50. PI3K-Akt Signalling Pathway, colour-coded according to fold change, 
where red means the gene was upregulated and green means the gene was 




Figure 51. Pathways in cancer, colour-coded according to fold change, where red 
means the gene was upregulated and green means the gene was downregulated.   
 
 
Figure 52. NOD-like receptor signalling pathway, colour-coded according to fold 
change, where red means the gene was upregulated and green means the gene 





Pathway Maps Comparing Solamargine-Treated and Untreated MGH cells 
 
Figure 53. TNF Signalling Pathway, colour-coded according to fold change, where 
red means the gene was upregulated and green means the gene was 




Figure 54. MAPK Signalling Pathway, colour-coded according to fold change, 
where red means the gene was upregulated and green means the gene was 




Figure 55. Toll-like receptor Signalling Pathway, colour-coded according to fold 
change, where red means the gene was upregulated and green means the gene 
was downregulated. 
